Target: 10 mg/day within several days Schizophrenia in adolescents (2.1) Oral: Start at mg once daily; Target: 10 mg/day

Size: px
Start display at page:

Download "Target: 10 mg/day within several days Schizophrenia in adolescents (2.1) Oral: Start at 2.5-5 mg once daily; Target: 10 mg/day"

Transcription

1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ZYPREXA sfely nd effectively. See full prescribing informtion for ZYPREXA. ZYPREXA (olnzpine) Tblet for Orl use ZYPREXA ZYDIS (olnzpine) Tblet, Orlly Disintegrting for Orl use ZYPREXA IntrMusculr (olnzpine) Injection, Powder, For Solution for Intrmusculr use Initil U.S. Approvl: WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing informtion for complete boxed wrning. Elderly ptients with dementi-relted psychosis treted with ntipsychotic drugs re t n incresed risk of deth. ZYPREXA is not pproved for the tretment of ptients with dementi-relted psychosis. (.,., 7.) When using ZYPREXA nd fluoxetine in combintion, lso refer to the Boxed Wrning section of the pckge insert for Symbyx. Efficcy ws estblished with Symbyx (olnzpine nd fluoxetine in combintion) in dults; refer to the product lbel for Symbyx DOSAGE AND ADMINISTRATION Schizophreni in dults (.) Orl: Strt t - mg once dily; Trget: mg/dy within severl dys Schizophreni in dolescents (.) Orl: Strt t.- mg once dily; Trget: mg/dy Bipolr I Disorder (mnic or mixed episodes) in dults (.) Orl: Strt t or mg once dily Bipolr I Disorder (mnic or mixed episodes) in dolescents (.) Orl: Strt t.- mg once dily; Trget: mg/dy Bipolr I Disorder (mnic or mixed episodes) with lithium or vlprote in dults (.) Orl: Strt t mg once dily Agittion ssocited with Schizophreni nd Bipolr I Mni in dults (.) IM: mg ( mg or 7. mg when cliniclly wrrnted) Assess for orthosttic hypotension prior to subsequent dosing (mx. doses - hrs prt) Depressive Episodes ssocited with Bipolr I Disorder in dults (.) Orl in combintion with fluoxetine: Strt t mg of orl olnzpine nd mg of fluoxetine once dily Depressive Episodes ssocited with Bipolr I Disorder in children nd dolescents (.) Orl in combintion with fluoxetine: Strt t. mg of orl olnzpine nd mg of fluoxetine once dily Tretment Resistnt Depression in dults (.) Orl in combintion with fluoxetine: Strt t mg of orl olnzpine nd mg of fluoxetine once dily RECENT MAJOR CHANGES Wrnings nd Precutions: Metbolic Chnges (.) / Hyperprolctinemi (.) / INDICATIONS AND USAGE ZYPREXA (olnzpine) is n typicl ntipsychotic indicted: As orl formultion for the: Tretment of schizophreni. (.) Adults: Efficcy ws estblished in three clinicl trils in ptients with schizophreni: two -week trils nd one mintennce tril. (.) Adolescents (ges -7): Efficcy ws estblished in one week tril in ptients with schizophreni (.). The incresed potentil (in dolescents compred with dults) for weight gin nd dyslipidemi my led clinicins to consider prescribing other drugs first in dolescents. (.) Acute tretment of mnic or mixed episodes ssocited with bipolr I disorder nd mintennce tretment of bipolr I disorder. (.) Adults: Efficcy ws estblished in three clinicl trils in ptients with mnic or mixed episodes of bipolr I disorder: two - to -week trils nd one mintennce tril. (.) Adolescents (ges -7): Efficcy ws estblished in one week tril in ptients with mnic or mixed episodes ssocited with bipolr I disorder (.). The incresed potentil (in dolescents compred with dults) for weight gin nd dyslipidemi my led clinicins to consider prescribing other drugs first in dolescents. (.) Mediction therpy for peditric ptients with schizophreni or bipolr I disorder should be undertken only fter thorough dignostic evlution nd with creful considertion of the potentil risks. (.) Adjunct to vlprote or lithium in the tretment of mnic or mixed episodes ssocited with bipolr I disorder. (.) Efficcy ws estblished in two -week clinicl trils in dults (.). Mintennce efficcy hs not been systemticlly evluted. As ZYPREXA IntrMusculr for the: Tretment of cute gittion ssocited with schizophreni nd bipolr I mni. (.) Efficcy ws estblished in three -dy trils in dults. (.) As ZYPREXA nd Fluoxetine in Combintion for the: Tretment of depressive episodes ssocited with bipolr I disorder. (.) Efficcy ws estblished with Symbyx (olnzpine nd fluoxetine in combintion); refer to the product lbel for Symbyx. Tretment of tretment resistnt depression. (.) Lower strting dose recommended in debilitted or phrmcodynmiclly sensitive ptients or ptients with predisposition to hypotensive rections, or with potentil for slowed metbolism. (.) my be given without regrd to mels. (.) ZYPREXA nd Fluoxetine in Combintion: Dosge djustments, if indicted, should be mde with the individul components ccording to efficcy nd tolerbility. (.,.) monotherpy is not indicted for the tretment of depressive episodes ssocited with bipolr I disorder or tretment resistnt depression. (.,.) Sfety of co-dministrtion of doses bove 8 mg olnzpine with 7 mg fluoxetine hs not been evluted in dults. (.,.) Sfety of co-dministrtion of doses bove mg olnzpine with mg fluoxetine hs not been evluted in children nd dolescents ges to 7. (.) DOSAGE FORMS AND STRENGTHS Tblets (not scored):.,, 7.,,, mg () Orlly Disintegrting Tblets (not scored):,,, mg () Intrmusculr Injection: mg vil () CONTRAINDICATIONS None with ZYPREXA monotherpy. When using ZYPREXA nd fluoxetine in combintion, lso refer to the Contrindictions section of the pckge insert for Symbyx. () When using ZYPREXA in combintion with lithium or vlprote, refer to the Contrindictions section of the pckge inserts for those products. () WARNINGS AND PRECAUTIONS Elderly Ptients with Dementi-Relted Psychosis: Incresed risk of deth nd incresed incidence of cerebrovsculr dverse events (e.g., stroke, trnsient ischemic ttck). (.) Suicide: The possibility of suicide ttempt is inherent in schizophreni nd in bipolr I disorder, nd close supervision of high-risk ptients should ccompny drug therpy; when using in combintion with fluoxetine, lso refer to the Boxed Wrning nd

2 Wrnings nd Precutions sections of the pckge insert for Symbyx. (.) Neuroleptic Mlignnt Syndrome: Mnge with immedite discontinution nd close monitoring. (.) Metbolic Chnges: Atypicl ntipsychotic drugs hve been ssocited with metbolic chnges including hyperglycemi, dyslipidemi, nd weight gin. (.) Hyperglycemi nd Dibetes Mellitus: In some cses extreme nd ssocited with ketocidosis or hyperosmolr com or deth, hs been reported in ptients tking olnzpine. Ptients tking olnzpine should be monitored for symptoms of hyperglycemi nd undergo fsting blood glucose testing t the beginning of, nd periodiclly during, tretment. (.) Dyslipidemi: Undesirble ltertions in lipids hve been observed. Approprite clinicl monitoring is recommended, including fsting blood lipid testing t the beginning of, nd periodiclly during, tretment. (.) Weight Gin: Potentil consequences of weight gin should be considered. Ptients should receive regulr monitoring of weight. (.) Trdive Dyskinesi: Discontinue if cliniclly pproprite. (.) Orthosttic Hypotension: Orthosttic hypotension ssocited with dizziness, tchycrdi, brdycrdi nd, in some ptients, syncope, my occur especilly during initil dose titrtion. Use cution in ptients with crdiovsculr disese, cerebrovsculr disese, nd those conditions tht could ffect hemodynmic responses. (.) Leukopeni, Neutropeni, nd Agrnulocytosis: Hs been reported with ntipsychotics, including ZYPREXA. Ptients with history of cliniclly significnt low white blood cell count (WBC) or drug induced leukopeni/neutropeni should hve their complete blood count (CBC) monitored frequently during the first few months of therpy nd discontinution of ZYPREXA should be considered t the first sign of cliniclly significnt decline in WBC in the bsence of other custive fctors. (.7) Seizures: Use cutiously in ptients with history of seizures or with conditions tht potentilly lower the seizure threshold. (.) Potentil for Cognitive nd Motor Impirment: Hs potentil to impir judgment, thinking, nd motor skills. Use cution when operting mchinery. (.) Hyperprolctinemi: My elevte prolctin levels. (.) Use in Combintion with Fluoxetine, Lithium or Vlprote: Also refer to the pckge inserts for Symbyx, lithium, or vlprote. (.) Lbortory Tests: Monitor fsting blood glucose nd lipid profiles t the beginning of, nd periodiclly during, tretment. (.) ADVERSE REACTIONS Most common dverse rections ( % nd t lest twice tht for plcebo) ssocited with: Orl Monotherpy: Schizophreni (Adults) posturl hypotension, constiption, weight gin, dizziness, personlity disorder, kthisi (.) Schizophreni (Adolescents) sedtion, weight incresed, hedche, incresed ppetite, dizziness, bdominl pin, pin in extremity, ftigue, dry mouth (.) Mnic or Mixed Episodes, Bipolr I Disorder (Adults) stheni, dry mouth, constiption, incresed ppetite, somnolence, dizziness, tremor (.) Mnic or Mixed Episodes, Bipolr I Disorder (Adolescents) sedtion, weight incresed, incresed ppetite, hedche, ftigue, dizziness, dry mouth, bdominl pin, pin in extremity (.) Combintion of ZYPREXA nd Lithium or Vlprote: Mnic or Mixed Episodes, Bipolr I Disorder (Adults) dry mouth, weight gin, incresed ppetite, dizziness, bck pin, constiption, speech disorder, incresed slivtion, mnesi, presthesi (.) ZYPREXA nd Fluoxetine in Combintion: Also refer to the Adverse Rections section of the pckge insert for Symbyx. () ZYPREXA IntrMusculr for Injection: Agittion with Schizophreni nd Bipolr I Mni (Adults) somnolence (.) To report SUSPECTED ADVERSE REACTIONS, contct Eli Lilly nd Compny t -8-LillyRx (-8--7) or FDA t -8-FDA-88 or DRUG INTERACTIONS Dizepm: My potentite orthosttic hypotension. (7., 7.) Alcohol: My potentite orthosttic hypotension. (7.) Crbmzepine: Incresed clernce of olnzpine. (7.) Fluvoxmine: My increse olnzpine levels. (7.) ZYPREXA nd Fluoxetine in Combintion: Also refer to the Drug Interctions section of the pckge insert for Symbyx. (7.) CNS Acting Drugs: Cution should be used when tken in combintion with other centrlly cting drugs nd lcohol. (7.) Antihypertensive Agents: Enhnced ntihypertensive effect. (7.) Levodop nd Dopmine Agonists: My ntgonize levodop/dopmine gonists. (7.) Lorzepm (IM): Incresed somnolence with IM olnzpine. (7.) Other Concomitnt Drug Therpy: When using olnzpine in combintion with lithium or vlprote, refer to the Drug Interctions sections of the pckge insert for those products. (7.) USE IN SPECIFIC POPULATIONS Pregnncy: ZYPREXA should be used during pregnncy only if the potentil benefit justifies the potentil risk to the fetus. (8.) Nursing Mothers: Brest-feeding is not recommended. (8.) Peditric Use: Sfety nd effectiveness of ZYPREXA in children < yers of ge hve not been estblished. Sfety nd effectiveness of ZYPREXA nd fluoxetine in combintion in children < yers of ge hve not been estblished. (8.) See 7 for PATIENT COUNSELING INFORMATION nd FDApproved Mediction Guide Revised: / FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS... INDICATIONS AND USAGE. Schizophreni. Bipolr I Disorder (Mnic or Mixed Episodes). Specil Considertions in Treting Peditric Schizophreni nd Bipolr I Disorder. ZYPREXA IntrMusculr: Agittion Associted with Schizophreni nd Bipolr I Mni. ZYPREXA nd Fluoxetine in Combintion: Depressive Episodes Associted with Bipolr I Disorder. ZYPREXA nd Fluoxetine in Combintion: Tretment Resistnt Depression DOSAGE AND ADMINISTRATION. Schizophreni...7 Bipolr I Disorder (Mnic or Mixed Episodes) Administrtion of ZYPREXA ZYDIS (olnzpine orlly disintegrting tblets) ZYPREXA IntrMusculr: Agittion Associted with Schizophreni nd Bipolr I Mni ZYPREXA nd Fluoxetine in Combintion: Depressive Episodes Associted with Bipolr I Disorder ZYPREXA nd Fluoxetine in Combintion: Tretment Resistnt Depression ZYPREXA nd Fluoxetine in Combintion: Dosing in Specil Popultions DOSAGE FORMS AND STRENGTHS CONTRAINDICATIONS WARNINGS AND PRECAUTIONS. Elderly Ptients with Dementi-Relted Psychosis

3 Suicide Neuroleptic Mlignnt Syndrome (NMS) Metbolic Chnges Trdive Dyskinesi Orthosttic Hypotension Leukopeni, Neutropeni, nd Agrnulocytosis Dysphgi Seizures Potentil for Cognitive nd Motor Impirment Body Temperture Regultion Use in Ptients with Concomitnt Illness Hyperprolctinemi Use in Combintion with Fluoxetine, Lithium, or Vlprote Lbortory Tests ADVERSE REACTIONS. Clinicl Trils Experience. Extrpyrmidl Symptoms. Other Adverse Rections. Vitl Signs nd Lbortory Studies. Postmrketing Experience 7 DRUG INTERACTIONS 7. Potentil for Other Drugs to Affect 7. Potentil for to Affect Other Drugs 8 USE IN SPECIFIC POPULATIONS 8. Pregnncy 8. Lbor nd Delivery 8. Nursing Mothers 8. Peditric Use 8. Geritric Use DRUG ABUSE AND DEPENDENCE. Dependence OVERDOSAGE. Humn Experience. Mngement of Overdose DESCRIPTION CLINICAL PHARMACOLOGY... Mechnism of Action Phrmcodynmics Phrmcokinetics NONCLINICAL TOXICOLOGY. Crcinogenesis, Mutgenesis, Impirment of Fertility. Animl Toxicology nd/or Phrmcology CLINICAL STUDIES. Schizophreni. Bipolr I Disorder (Mnic or Mixed Episodes). Agittion Associted with Schizophreni nd Bipolr I Mni HOW SUPPLIED/STORAGE AND HANDLING. How Supplied. Storge nd Hndling 7 PATIENT COUNSELING INFORMATION 7. Informtion on Mediction Guide 7. Elderly Ptients with Dementi-Relted Psychosis: Incresed Mortlity nd Cerebrovsculr Adverse Events (CVAE), Including Stroke 7. Neuroleptic Mlignnt Syndrome (NMS) 7. Hyperglycemi nd Dibetes Mellitus 7. Dyslipidemi 7. Weight Gin 7.7 Orthosttic Hypotension 7.8 Potentil for Cognitive nd Motor Impirment 7. Body Temperture Regultion 7. Concomitnt Mediction 7. Alcohol 7. Phenylketonurics 7. Use in Specific Popultions 7. Need for Comprehensive Tretment Progrm in Peditric Ptients *Sections or subsections omitted from the full prescribing informtion re not listed FULL PRESCRIBING INFORMATION WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly ptients with dementi-relted psychosis treted with ntipsychotic drugs re t n incresed risk of deth. Anlyses of seventeen plcebo-controlled trils (modl durtion of weeks), lrgely in ptients tking typicl ntipsychotic drugs, reveled risk of deth in drug-treted ptients of between. to.7 times the risk of deth in plcebo-treted ptients. Over the course of typicl -week controlled tril, the rte of deth in drug-treted ptients ws bout.%, compred to rte of bout.% in the plcebo group. Although the cuses of deth were vried, most of the deths ppered to be either crdiovsculr (e.g., hert filure, sudden deth) or infectious (e.g., pneumoni) in nture. Observtionl studies suggest tht, similr to typicl ntipsychotic drugs, tretment with conventionl ntipsychotic drugs my increse mortlity. The extent to which the findings of incresed mortlity in observtionl studies my be ttributed to the ntipsychotic drug s opposed to some chrcteristic(s) of the ptients is not cler. ZYPREXA (olnzpine) is not pproved for the tretment of ptients with dementi-relted psychosis [see Wrnings nd Precutions (.,.) nd Ptient Counseling Informtion (7.)]. When using ZYPREXA nd fluoxetine in combintion, lso refer to the Boxed Wrning section of the pckge insert for Symbyx.. INDICATIONS AND USAGE Schizophreni Orl ZYPREXA is indicted for the tretment of schizophreni. Efficcy ws estblished in three clinicl trils in dult ptients with schizophreni: two -week trils nd one mintennce tril. In dolescent ptients with schizophreni (ges -7), efficcy ws estblished in one -week tril [see Clinicl Studies (.)]. When deciding mong the lterntive tretments vilble for dolescents, clinicins should consider the incresed potentil (in dolescents s compred with dults) for weight gin nd dyslipidemi. Clinicins should consider

4 the potentil long-term risks when prescribing to dolescents, nd in mny cses this my led them to consider prescribing other drugs first in dolescents [see Wrnings nd Precutions (.)].. Bipolr I Disorder (Mnic or Mixed Episodes) Monotherpy Orl ZYPREXA is indicted for the cute tretment of mnic or mixed episodes ssocited with bipolr I disorder nd mintennce tretment of bipolr I disorder. Efficcy ws estblished in three clinicl trils in dult ptients with mnic or mixed episodes of bipolr I disorder: two - to -week trils nd one monotherpy mintennce tril. In dolescent ptients with mnic or mixed episodes ssocited with bipolr I disorder (ges -7), efficcy ws estblished in one -week tril [see Clinicl Studies (.)]. When deciding mong the lterntive tretments vilble for dolescents, clinicins should consider the incresed potentil (in dolescents s compred with dults) for weight gin nd dyslipidemi. Clinicins should consider the potentil long-term risks when prescribing to dolescents, nd in mny cses this my led them to consider prescribing other drugs first in dolescents [see Wrnings nd Precutions (.)]. Adjunctive Therpy to Lithium or Vlprote Orl ZYPREXA is indicted for the tretment of mnic or mixed episodes ssocited with bipolr I disorder s n djunct to lithium or vlprote. Efficcy ws estblished in two -week clinicl trils in dults. The effectiveness of djunctive therpy for longer-term use hs not been systemticlly evluted in controlled trils [see Clinicl Studies (.)].. Specil Considertions in Treting Peditric Schizophreni nd Bipolr I Disorder Peditric schizophreni nd bipolr I disorder re serious mentl disorders; however, dignosis cn be chllenging. For peditric schizophreni, symptom profiles cn be vrible, nd for bipolr I disorder, peditric ptients my hve vrible ptterns of periodicity of mnic or mixed symptoms. It is recommended tht mediction therpy for peditric schizophreni nd bipolr I disorder be initited only fter thorough dignostic evlution hs been performed nd creful considertion given to the risks ssocited with mediction tretment. Mediction tretment for both peditric schizophreni nd bipolr I disorder should be prt of totl tretment progrm tht often includes psychologicl, eductionl nd socil interventions.. ZYPREXA IntrMusculr: Agittion Associted with Schizophreni nd Bipolr I Mni ZYPREXA IntrMusculr is indicted for the tretment of cute gittion ssocited with schizophreni nd bipolr I mni. Efficcy ws demonstrted in short-term ( hours of IM tretment) plcebo-controlled trils in gitted dult inptients with: schizophreni or bipolr I disorder (mnic or mixed episodes) [see Clinicl Studies (.)]. Psychomotor gittion is defined in DSM-IV s excessive motor ctivity ssocited with feeling of inner tension. Ptients experiencing gittion often mnifest behviors tht interfere with their dignosis nd cre, e.g., thretening behviors, esclting or urgently distressing behvior, or self-exhusting behvior, leding clinicins to the use of intrmusculr ntipsychotic medictions to chieve immedite control of the gittion.. ZYPREXA nd Fluoxetine in Combintion: Depressive Episodes Associted with Bipolr I Disorder Orl ZYPREXA nd fluoxetine in combintion is indicted for the tretment of depressive episodes ssocited with bipolr I disorder, bsed on clinicl studies. When using ZYPREXA nd fluoxetine in combintion, refer to the Clinicl Studies section of the pckge insert for Symbyx. ZYPREXA monotherpy is not indicted for the tretment of depressive episodes ssocited with bipolr I disorder.. ZYPREXA nd Fluoxetine in Combintion: Tretment Resistnt Depression Orl ZYPREXA nd fluoxetine in combintion is indicted for the tretment of tretment resistnt depression (mjor depressive disorder in ptients who do not respond to seprte trils of different ntidepressnts of dequte dose nd durtion in the current episode), bsed on clinicl studies in dult ptients. When using ZYPREXA nd fluoxetine in combintion, refer to the Clinicl Studies section of the pckge insert for Symbyx. ZYPREXA monotherpy is not indicted for the tretment of tretment resistnt depression. DOSAGE AND ADMINISTRATION. Schizophreni Adults Dose Selection Orl olnzpine should be dministered on once--dy schedule without regrd to mels, generlly beginning with to mg initilly, with trget dose of mg/dy within severl dys. Further dosge djustments, if indicted, should generlly occur t intervls of not less thn week, since stedy stte for olnzpine would not be chieved for pproximtely week in the typicl ptient. When dosge djustments re necessry, dose increments/decrements of mg QD re recommended. Efficcy in schizophreni ws demonstrted in dose rnge of to mg/dy in clinicl trils. However, doses bove mg/dy were not demonstrted to be more efficcious thn the mg/dy dose. An increse to dose greter thn the trget dose of mg/dy (i.e., to dose of mg/dy or greter) is recommended only fter clinicl ssessment. is not indicted for use in doses bove mg/dy. Dosing in Specil Popultions The recommended strting dose is mg in ptients who re debilitted, who hve predisposition to hypotensive rections, who otherwise exhibit combintion of fctors tht my result in slower

5 metbolism of olnzpine (e.g., nonsmoking femle ptients yers of ge), or who my be more phrmcodynmiclly sensitive to olnzpine [see Wrnings nd Precutions (.), Drug Interctions (7), nd Clinicl Phrmcology (.)]. When indicted, dose escltion should be performed with cution in these ptients. Mintennce Tretment The effectiveness of orl olnzpine, mg/dy to mg/dy, in mintining tretment response in schizophrenic ptients who hd been stble on ZYPREXA for pproximtely 8 weeks nd were then followed for relpse hs been demonstrted in plcebo-controlled tril [see Clinicl Studies (.)]. The physicin who elects to use ZYPREXA for extended periods should periodiclly reevlute the long-term usefulness of the drug for the individul ptient. Adolescents Dose Selection Orl olnzpine should be dministered on once--dy schedule without regrd to mels with recommended strting dose of. or mg, with trget dose of mg/dy. Efficcy in dolescents with schizophreni ws demonstrted bsed on flexible dose rnge of. to mg/dy in clinicl trils, with men modl dose of. mg/dy (men dose of. mg/dy). When dosge djustments re necessry, dose increments/decrements of. or mg re recommended. The sfety nd effectiveness of doses bove mg/dy hve not been evluted in clinicl trils [see Clinicl Studies (.)]. Mintennce Tretment The efficcy of ZYPREXA for the mintennce tretment of schizophreni in the dolescent popultion hs not been systemticlly evluted; however, mintennce efficcy cn be extrpolted from dult dt long with comprisons of olnzpine phrmcokinetic prmeters in dult nd dolescent ptients. Thus, it is generlly recommended tht responding ptients be continued beyond the cute response, but t the lowest dose needed to mintin remission. Ptients should be periodiclly ressessed to determine the need for mintennce tretment.. Bipolr I Disorder (Mnic or Mixed Episodes) Adults Dose Selection for Monotherpy Orl olnzpine should be dministered on once--dy schedule without regrd to mels, generlly beginning with or mg. Dosge djustments, if indicted, should generlly occur t intervls of not less thn hours, reflecting the procedures in the plcebo-controlled trils. When dosge djustments re necessry, dose increments/decrements of mg QD re recommended. Short-term (- weeks) ntimnic efficcy ws demonstrted in dose rnge of mg to mg/dy in clinicl trils. The sfety of doses bove mg/dy hs not been evluted in clinicl trils [see Clinicl Studies (.)]. Mintennce Monotherpy The benefit of mintining bipolr I ptients on monotherpy with orl ZYPREXA t dose of to mg/dy, fter chieving responder sttus for n verge durtion of weeks, ws demonstrted in controlled tril [see Clinicl Studies (.)]. The physicin who elects to use ZYPREXA for extended periods should periodiclly reevlute the long-term usefulness of the drug for the individul ptient. Dose Selection for Adjunctive Tretment When dministered s djunctive tretment to lithium or vlprote, orl olnzpine dosing should generlly begin with mg once--dy without regrd to mels. Antimnic efficcy ws demonstrted in dose rnge of mg to mg/dy in clinicl trils [see Clinicl Studies (.)]. The sfety of doses bove mg/dy hs not been evluted in clinicl trils. Adolescents Dose Selection Orl olnzpine should be dministered on once--dy schedule without regrd to mels with recommended strting dose of. or mg, with trget dose of mg/dy. Efficcy in dolescents with bipolr I disorder (mnic or mixed episodes) ws demonstrted bsed on flexible dose rnge of. to mg/dy in clinicl trils, with men modl dose of.7 mg/dy (men dose of 8. mg/dy). When dosge djustments re necessry, dose increments/decrements of. or mg re recommended. The sfety nd effectiveness of doses bove mg/dy hve not been evluted in clinicl trils [see Clinicl Studies (.)]. Mintennce Tretment The efficcy of ZYPREXA for the mintennce tretment of bipolr I disorder in the dolescent popultion hs not been evluted; however, mintennce efficcy cn be extrpolted from dult dt long with comprisons of olnzpine phrmcokinetic prmeters in dult nd dolescent ptients. Thus, it is generlly recommended tht responding ptients be continued beyond the cute response, but t the lowest dose needed to mintin remission. Ptients should be periodiclly ressessed to determine the need for mintennce tretment.. Administrtion of ZYPREXA ZYDIS (olnzpine orlly disintegrting tblets) After opening schet, peel bck foil on blister. Do not push tblet through foil. Immeditely upon opening the blister, using dry hnds, remove tblet nd plce entire ZYPREXA ZYDIS in the mouth. Tblet disintegrtion occurs rpidly in sliv so it cn be esily swllowed with or without liquid.. ZYPREXA IntrMusculr: Agittion Associted with Schizophreni nd Bipolr I Mni Dose Selection for Agitted Adult Ptients with Schizophreni nd Bipolr I Mni The efficcy of intrmusculr olnzpine for injection in controlling gittion in these disorders ws demonstrted in dose rnge of. mg to mg. The recommended dose in these ptients is mg. A lower dose of or 7. mg my be considered when clinicl fctors

6 wrrnt [see Clinicl Studies (.)]. If gittion wrrnting dditionl intrmusculr doses persists following the initil dose, subsequent doses up to mg my be given. However, the efficcy of repeted doses of intrmusculr olnzpine for injection in gitted ptients hs not been systemticlly evluted in controlled clinicl trils. Also, the sfety of totl dily doses greter thn mg, or mg injections given more frequently thn hours fter the initil dose, nd hours fter the second dose hve not been evluted in clinicl trils. Mximl dosing of intrmusculr olnzpine (e.g., doses of mg dministered - hours prt) my be ssocited with substntil occurrence of significnt orthosttic hypotension [see Wrnings nd Precutions (.)]. Thus, it is recommended tht ptients requiring subsequent intrmusculr injections be ssessed for orthosttic hypotension prior to the dministrtion of ny subsequent doses of intrmusculr olnzpine for injection. The dministrtion of n dditionl dose to ptient with cliniclly significnt posturl chnge in systolic blood pressure is not recommended. If ongoing olnzpine therpy is cliniclly indicted, orl olnzpine my be initited in rnge of - mg/dy s soon s cliniclly pproprite [see Dosge nd Administrtion (.,.)]. Intrmusculr Dosing in Specil Popultions A dose of mg/injection should be considered for geritric ptients or when other clinicl fctors wrrnt. A lower dose of. mg/injection should be considered for ptients who otherwise might be debilitted, be predisposed to hypotensive rections, or be more phrmcodynmiclly sensitive to olnzpine [see Wrnings nd Precutions (.), Drug Interctions (7), nd Clinicl Phrmcology (.)]. Administrtion of ZYPREXA IntrMusculr ZYPREXA IntrMusculr is intended for intrmusculr use only. Do not dminister intrvenously or subcutneously. Inject slowly, deep into the muscle mss. Prenterl drug products should be inspected visully for prticulte mtter nd discolortion prior to dministrtion, whenever solution nd continer permit. Directions for Preprtion of ZYPREXA IntrMusculr with Sterile Wter for Injection Dissolve the contents of the vil using. ml of Sterile Wter for Injection to provide solution contining pproximtely mg/ml of olnzpine. The resulting solution should pper cler nd yellow. ZYPREXA IntrMusculr reconstituted with Sterile Wter for Injection should be used immeditely (within hour) fter reconstitution. Discrd ny unused portion. The following tble provides injection volumes for delivering vrious doses of intrmusculr olnzpine for injection reconstituted with Sterile Wter for Injection. Dose, mg 7.. Volume of Injection, ml Withdrw totl contents of vil.. Physicl Incomptibility Informtion ZYPREXA IntrMusculr should be reconstituted only with Sterile Wter for Injection. ZYPREXA IntrMusculr should not be combined in syringe with dizepm injection becuse precipittion occurs when these products re mixed. Lorzepm injection should not be used to reconstitute ZYPREXA IntrMusculr s this combintion results in delyed reconstitution time. ZYPREXA IntrMusculr should not be combined in syringe with hloperidol injection becuse the resulting low ph hs been shown to degrde olnzpine over time.. ZYPREXA nd Fluoxetine in Combintion: Depressive Episodes Associted with Bipolr I Disorder When using ZYPREXA nd fluoxetine in combintion, lso refer to the Clinicl Studies section of the pckge insert for Symbyx. Adults Orl olnzpine should be dministered in combintion with fluoxetine once dily in the evening, without regrd to mels, generlly beginning with mg of orl olnzpine nd mg of fluoxetine. Dosge djustments, if indicted, cn be mde ccording to efficcy nd tolerbility within dose rnges of orl olnzpine to. mg nd fluoxetine to mg. Antidepressnt efficcy ws demonstrted with ZYPREXA nd fluoxetine in combintion in dult ptients with dose rnge of olnzpine to mg nd fluoxetine to mg. Sfety of co-dministrtion of doses bove 8 mg olnzpine with 7 mg fluoxetine hs not been evluted in clinicl studies. Children nd Adolescents (-7 yers of ge) Orl olnzpine should be dministered in combintion with fluoxetine once dily in the evening, without regrd to mels, generlly beginning with. mg of orl olnzpine nd mg of fluoxetine. Dosge djustments, if indicted, cn be mde ccording to efficcy nd tolerbility. Sfety of co-dministrtion of doses bove mg olnzpine with mg fluoxetine hs not been evluted in peditric clinicl studies. Sfety nd efficcy of ZYPREXA nd fluoxetine in combintion ws determined in clinicl trils supporting pprovl of Symbyx (fixed dose combintion of ZYPREXA nd fluoxetine). Symbyx is dosed between mg/ mg (olnzpine/fluoxetine) per dy nd mg/ mg (olnzpine/fluoxetine) per dy. The following tble demonstrtes the pproprite individul component doses of ZYPREXA nd fluoxetine versus Symbyx. Dosge djustments, if indicted, should be mde with the individul components ccording to efficcy nd tolerbility.

7 7 Tble : Approximte Dose Correspondence Between Symbyx nd the Combintion of ZYPREXA nd Fluoxetine For Use in Combintion Symbyx ZYPREXA Fluoxetine (mg/dy) (mg/dy) (mg/dy) mg olnzpine/ mg fluoxetine. mg olnzpine/ mg fluoxetine mg olnzpine/ mg fluoxetine +. mg olnzpine/ mg fluoxetine + mg olnzpine/ mg fluoxetine +. + Symbyx (olnzpine/fluoxetine HCl) is fixed-dose combintion of ZYPREXA nd fluoxetine. While there is no body of evidence to nswer the question of how long ptient treted with ZYPREXA nd fluoxetine in combintion should remin on it, it is generlly ccepted tht bipolr I disorder, including the depressive episodes ssocited with bipolr I disorder, is chronic illness requiring chronic tretment. The physicin should periodiclly reexmine the need for continued phrmcotherpy. ZYPREXA monotherpy is not indicted for the tretment of depressive episodes ssocited with bipolr I disorder.. ZYPREXA nd Fluoxetine in Combintion: Tretment Resistnt Depression When using ZYPREXA nd fluoxetine in combintion, lso refer to the Clinicl Studies section of the pckge insert for Symbyx. Orl olnzpine should be dministered in combintion with fluoxetine once dily in the evening, without regrd to mels, generlly beginning with mg of orl olnzpine nd mg of fluoxetine. Dosge djustments, if indicted, cn be mde ccording to efficcy nd tolerbility within dose rnges of orl olnzpine to mg nd fluoxetine to mg. Antidepressnt efficcy ws demonstrted with olnzpine nd fluoxetine in combintion in dult ptients with dose rnge of olnzpine to 8 mg nd fluoxetine to mg. Sfety nd efficcy of olnzpine in combintion with fluoxetine ws determined in clinicl trils supporting pprovl of Symbyx (fixed dose combintion of olnzpine nd fluoxetine). Symbyx is dosed between mg/ mg (olnzpine/fluoxetine) per dy nd mg/ mg (olnzpine/fluoxetine) per dy. Tble bove demonstrtes the pproprite individul component doses of ZYPREXA nd fluoxetine versus Symbyx. Dosge djustments, if indicted, should be mde with the individul components ccording to efficcy nd tolerbility. While there is no body of evidence to nswer the question of how long ptient treted with ZYPREXA nd fluoxetine in combintion should remin on it, it is generlly ccepted tht tretment resistnt depression (mjor depressive disorder in dult ptients who do not respond to seprte trils of different ntidepressnts of dequte dose nd durtion in the current episode) is chronic illness requiring chronic tretment. The physicin should periodiclly reexmine the need for continued phrmcotherpy. Sfety of co-dministrtion of doses bove 8 mg olnzpine with 7 mg fluoxetine hs not been evluted in clinicl studies. ZYPREXA monotherpy is not indicted for tretment of tretment resistnt depression (mjor depressive disorder in ptients who do not respond to ntidepressnts of dequte dose nd durtion in the current episode)..7 ZYPREXA nd Fluoxetine in Combintion: Dosing in Specil Popultions The strting dose of orl olnzpine.- mg with fluoxetine mg should be used for ptients with predisposition to hypotensive rections, ptients with heptic impirment, or ptients who exhibit combintion of fctors tht my slow the metbolism of olnzpine or fluoxetine in combintion (femle gender, geritric ge, nonsmoking sttus), or those ptients who my be phrmcodynmiclly sensitive to olnzpine. Dosing modifiction my be necessry in ptients who exhibit combintion of fctors tht my slow metbolism. When indicted, dose escltion should be performed with cution in these ptients. ZYPREXA nd fluoxetine in combintion hve not been systemticlly studied in ptients over yers of ge or in ptients under yers of ge [see Wrnings nd Precutions (.), Drug Interctions (7), nd Clinicl Phrmcology (.)]. DOSAGE FORMS AND STRENGTHS The ZYPREXA. mg, mg, 7. mg, nd mg tblets re white, round, nd imprinted in blue ink with LILLY nd tblet number. The mg tblets re ellipticl, blue, nd debossed with LILLY nd tblet number. The mg tblets re ellipticl, pink, nd debossed with LILLY nd tblet number. Tblets re not scored. The tblets re vilble s follows: Tblet No. Identifiction. mg LILLY mg LILLY TABLET STRENGTH 7. mg mg 7 LILLY LILLY 7 mg LILLY mg LILLY

8 8 ZYPREXA ZYDIS (olnzpine orlly disintegrting tblets) re yellow, round, nd debossed with the tblet strength. Tblets re not scored. The tblets re vilble s follows: ZYPREXA ZYDIS Tblets Tblet No. Debossed mg TABLET STRENGTH mg mg mg ZYPREXA IntrMusculr is vilble in mg vil (s). CONTRAINDICATIONS None with ZYPREXA monotherpy. When using ZYPREXA nd fluoxetine in combintion, lso refer to the Contrindictions section of the pckge insert for Symbyx. For specific informtion bout the contrindictions of lithium or vlprote, refer to the Contrindictions section of the pckge inserts for these other products. WARNINGS AND PRECAUTIONS When using ZYPREXA nd fluoxetine in combintion, lso refer to the Wrnings nd Precutions section of the pckge insert for Symbyx.. Elderly Ptients with Dementi-Relted Psychosis Incresed Mortlity Elderly ptients with dementi-relted psychosis treted with ntipsychotic drugs re t n incresed risk of deth. ZYPREXA is not pproved for the tretment of ptients with dementi-relted psychosis [see Boxed Wrning, Wrnings nd Precutions (.), nd Ptient Counseling Informtion (7.)]. In plcebo-controlled clinicl trils of elderly ptients with dementi-relted psychosis, the incidence of deth in olnzpine-treted ptients ws significntly greter thn plcebo-treted ptients (.% vs.%, respectively). Cerebrovsculr Adverse Events (CVAE), Including Stroke Cerebrovsculr dverse events (e.g., stroke, trnsient ischemic ttck), including ftlities, were reported in ptients in trils of olnzpine in elderly ptients with dementi-relted psychosis. In plcebo-controlled trils, there ws significntly higher incidence of cerebrovsculr dverse events in ptients treted with olnzpine compred to ptients treted with plcebo. is not pproved for the tretment of ptients with dementi-relted psychosis [see Boxed Wrning nd Ptient Counseling Informtion (7.)].. Suicide The possibility of suicide ttempt is inherent in schizophreni nd in bipolr I disorder, nd close supervision of high-risk ptients should ccompny drug therpy. Prescriptions for olnzpine should be written for the smllest quntity of tblets consistent with good ptient mngement, in order to reduce the risk of overdose.. Neuroleptic Mlignnt Syndrome (NMS) A potentilly ftl symptom complex sometimes referred to s Neuroleptic Mlignnt Syndrome (NMS) hs been reported in ssocition with dministrtion of ntipsychotic drugs, including olnzpine. Clinicl mnifesttions of NMS re hyperpyrexi, muscle rigidity, ltered mentl sttus nd evidence of utonomic instbility (irregulr pulse or blood pressure, tchycrdi, diphoresis nd crdic dysrhythmi). Additionl signs my include elevted cretinine phosphokinse, myoglobinuri (rhbdomyolysis), nd cute renl filure. The dignostic evlution of ptients with this syndrome is complicted. In rriving t dignosis, it is importnt to exclude cses where the clinicl presenttion includes both serious medicl illness (e.g., pneumoni, systemic infection, etc.) nd untreted or indequtely treted extrpyrmidl signs nd symptoms (EPS). Other importnt considertions in the differentil dignosis include centrl nticholinergic toxicity, het stroke, drug fever, nd primry centrl nervous system pthology. The mngement of NMS should include: ) immedite discontinution of ntipsychotic drugs nd other drugs not essentil to concurrent therpy; ) intensive symptomtic tretment nd medicl monitoring; nd ) tretment of ny concomitnt serious medicl problems for which specific tretments re vilble. There is no generl greement bout specific phrmcologicl tretment regimens for NMS. If ptient requires ntipsychotic drug tretment fter recovery from NMS, the potentil reintroduction of drug therpy should be crefully considered. The ptient should be crefully monitored, since recurrences of NMS hve been reported [see Ptient Counseling Informtion (7.)].. Metbolic Chnges Atypicl ntipsychotic drugs hve been ssocited with metbolic chnges including hyperglycemi, dyslipidemi, nd weight gin. Metbolic chnges my be ssocited with incresed crdiovsculr/cerebrovsculr risk. s specific metbolic profile is presented below. Hyperglycemi nd Dibetes Mellitus

9 Physicins should consider the risks nd benefits when prescribing olnzpine to ptients with n estblished dignosis of dibetes mellitus, or hving borderline incresed blood glucose level (fsting - mg/dl, nonfsting - mg/dl). Ptients tking olnzpine should be monitored regulrly for worsening of glucose control. Ptients strting tretment with olnzpine should undergo fsting blood glucose testing t the beginning of tretment nd periodiclly during tretment. Any ptient treted with typicl ntipsychotics should be monitored for symptoms of hyperglycemi including polydipsi, polyuri, polyphgi, nd wekness. Ptients who develop symptoms of hyperglycemi during tretment with typicl ntipsychotics should undergo fsting blood glucose testing. In some cses, hyperglycemi hs resolved when the typicl ntipsychotic ws discontinued; however, some ptients required continution of nti-dibetic tretment despite discontinution of the suspect drug [see Ptient Counseling Informtion (7.)]. Hyperglycemi, in some cses extreme nd ssocited with ketocidosis or hyperosmolr com or deth, hs been reported in ptients treted with typicl ntipsychotics including olnzpine. Assessment of the reltionship between typicl ntipsychotic use nd glucose bnormlities is complicted by the possibility of n incresed bckground risk of dibetes mellitus in ptients with schizophreni nd the incresing incidence of dibetes mellitus in the generl popultion. Epidemiologicl studies suggest n incresed risk of tretment-emergent hyperglycemi-relted dverse rections in ptients treted with the typicl ntipsychotics. While reltive risk estimtes re inconsistent, the ssocition between typicl ntipsychotics nd increses in glucose levels ppers to fll on continuum nd olnzpine ppers to hve greter ssocition thn some other typicl ntipsychotics. Men increses in blood glucose hve been observed in ptients treted (medin exposure of. months) with olnzpine in phse of the Clinicl Antipsychotic Trils of Intervention Effectiveness (CATIE). The men increse of serum glucose (fsting nd nonfsting smples) from bseline to the verge of the highest serum concentrtions ws. mg/dl. In study of helthy volunteers, subjects who received olnzpine (N=) for weeks hd men increse compred to bseline in fsting blood glucose of. mg/dl. -treted subjects (N=) hd men increse in fsting blood glucose compred to bseline of. mg/dl. Monotherpy in Adults In n nlysis of plcebo-controlled dult olnzpine monotherpy studies with medin tretment durtion of pproximtely weeks, olnzpine ws ssocited with greter men chnge in fsting glucose levels compred to plcebo (.7 mg/dl versus.7 mg/dl). The difference in men chnges between olnzpine nd plcebo ws greter in ptients with evidence of glucose dysregultion t bseline (ptients dignosed with dibetes mellitus or relted dverse rections, ptients treted with nti-dibetic gents, ptients with bseline rndom glucose level mg/dl, nd/or bseline fsting glucose level mg/dl). -treted ptients hd greter men HbAc increse from bseline of.% (medin exposure dys), compred to men HbAc decrese of.% in plcebo-treted subjects (medin exposure 7 dys). In n nlysis of 8 plcebo-controlled studies (medin tretment exposure - weeks),.% of olnzpine-treted subjects (N=8) hd tretment-emergent glycosuri compred to.8% of plcebo-treted subjects (N=). Tble shows short-term nd long-term chnges in fsting glucose levels from dult olnzpine monotherpy studies. Tble : Chnges in Fsting Glucose Levels from Adult Monotherpy Studies Up to weeks At lest 8 weeks exposure exposure Lbortory Ctegory Chnge (t lest once) Tretment Anlyte from Bseline Arm N Ptients N Ptients Norml to High.%.8% Fsting (< mg/dl to mg/dl).% NA NA Glucose Borderline to High 78 7.% 7.% ( mg/dl nd < mg/dl to mg/dl).% NA NA Not Applicble. The men chnge in fsting glucose for ptients exposed t lest 8 weeks ws. mg/dl (N=87). In nlyses of ptients who completed - months of olnzpine therpy, men chnge in fsting nd nonfsting glucose levels continued to increse over time. Monotherpy in Adolescents The sfety nd efficcy of olnzpine hve not been estblished in ptients under the ge of yers. In n nlysis of plcebo-controlled olnzpine monotherpy studies of dolescent ptients, including those with schizophreni ( weeks) or bipolr I disorder (mnic or mixed episodes) ( weeks), olnzpine ws ssocited with greter men chnge from bseline in fsting glucose levels compred to plcebo (.8 mg/dl versus -. mg/dl). The men chnge in fsting glucose for dolescents exposed t lest weeks ws. mg/dl (N=). Tble shows short-term nd long-term chnges in fsting blood glucose from dolescent olnzpine monotherpy studies. Tble : Chnges in Fsting Glucose Levels from Adolescent Monotherpy Studies

10 Up to weeks exposure Lbortory Anlyte Ctegory Chnge (t lest once) from Bseline Norml to High Fsting (< mg/dl to mg/dl) Glucose Borderline to High ( mg/dl nd < mg/dl to mg/dl) Not Applicble. Tretment Arm N Ptients %.%.% % At lest weeks exposure N 8 NA NA Ptients.% NA.% NA Dyslipidemi Undesirble ltertions in lipids hve been observed with olnzpine use. Clinicl monitoring, including bseline nd periodic follow-up lipid evlutions in ptients using olnzpine, is recommended [see Ptient Counseling Informtion (7.)]. Cliniclly significnt, nd sometimes very high (> mg/dl), elevtions in triglyceride levels hve been observed with olnzpine use. Modest men increses in totl cholesterol hve lso been seen with olnzpine use. Monotherpy in Adults In n nlysis of plcebo-controlled olnzpine monotherpy studies with tretment durtion up to weeks, olnzpine-treted ptients hd increses from bseline in men fsting totl cholesterol, LDL cholesterol, nd triglycerides of. mg/dl,. mg/dl, nd.8 mg/dl respectively compred to decreses from bseline in men fsting totl cholesterol, LDL cholesterol, nd triglycerides of. mg/dl,. mg/dl, nd.7 mg/dl for plcebo-treted ptients. For fsting HDL cholesterol, no cliniclly meningful differences were observed between olnzpine-treted ptients nd plcebo-treted ptients. Men increses in fsting lipid vlues (totl cholesterol, LDL cholesterol, nd triglycerides) were greter in ptients without evidence of lipid dysregultion t bseline, where lipid dysregultion ws defined s ptients dignosed with dyslipidemi or relted dverse rections, ptients treted with lipid lowering gents, or ptients with high bseline lipid levels. In long-term studies (t lest 8 weeks), ptients hd increses from bseline in men fsting totl cholesterol, LDL cholesterol, nd triglycerides of. mg/dl,. mg/dl, nd 8.7 mg/dl, respectively, nd men decrese in fsting HDL cholesterol of. mg/dl. In n nlysis of ptients who completed months of therpy, the men nonfsting totl cholesterol did not increse further fter pproximtely - months. The proportion of ptients who hd chnges (t lest once) in totl cholesterol, LDL cholesterol or triglycerides from norml or borderline to high, or chnges in HDL cholesterol from norml or borderline to low, ws greter in longterm studies (t lest 8 weeks) s compred with short-term studies. Tble shows ctegoricl chnges in fsting lipids vlues. Tble : Chnges in Fsting Lipids Vlues from Adult Monotherpy Studies Up to weeks At lest 8 weeks exposure exposure Lbortory Ctegory Chnge (t lest once) Tretment Anlyte from Bseline Arm N Ptients N Ptients Increse by mg/dl 7.% 87.%.% NA NA Fsting Norml to High 7.%.% Triglycerides (< mg/dl to mg/dl).% NA NA Borderline to High.% 7 7.7% ( mg/dl nd < mg/dl to mg/dl).% NA NA Increse by mg/dl Fsting Totl Cholesterol Norml to High (< mg/dl to mg/dl) Borderline to High ( mg/dl nd < mg/dl to mg/dl) Increse by mg/dl Fsting LDL Cholesterol Norml to High (< mg/dl to mg/dl) Borderline to High ( mg/dl nd < mg/dl to mg/dl) 7 7.%.%.8%.%.%.% 8 NA 8 NA NA.% NA.8% NA.% NA 8 7.7%.% %.%.% 8.% 8 NA NA 8 NA.8% NA 7.% NA.% NA

11 Not Applicble. In phse of the Clinicl Antipsychotic Trils of Intervention Effectiveness (CATIE), over medin exposure of. months, the men increse in triglycerides in ptients tking olnzpine ws. mg/dl. In phse of CATIE, the men increse in totl cholesterol ws. mg/dl. Monotherpy in Adolescents The sfety nd efficcy of olnzpine hve not been estblished in ptients under the ge of yers. In n nlysis of plcebo-controlled olnzpine monotherpy studies of dolescents, including those with schizophreni ( weeks) or bipolr I disorder (mnic or mixed episodes) ( weeks), olnzpinetreted dolescents hd increses from bseline in men fsting totl cholesterol, LDL cholesterol, nd triglycerides of. mg/dl,. mg/dl, nd 8. mg/dl, respectively, compred to increses from bseline in men fsting totl cholesterol nd LDL cholesterol of. mg/dl nd. mg/dl, nd decrese in triglycerides of. mg/dl for plcebotreted dolescents. For fsting HDL cholesterol, no cliniclly meningful differences were observed between olnzpinetreted dolescents nd plcebo-treted dolescents. In long-term studies (t lest weeks), dolescents hd increses from bseline in men fsting totl cholesterol, LDL cholesterol, nd triglycerides of. mg/dl,. mg/dl, nd. mg/dl, respectively, nd men decrese in fsting HDL cholesterol of. mg/dl. Tble shows ctegoricl chnges in fsting lipids vlues in dolescents. Tble : Chnges in Fsting Lipids Vlues from Adolescent Monotherpy Studies Up to weeks At lest weeks exposure exposure Lbortory Ctegory Chnge (t lest once) Tretment Anlyte from Bseline Arm N Ptients N Ptients Increse by mg/dl 8 7.%.%.% NA NA Fsting Norml to High 7.%.% Triglycerides (< mg/dl to > mg/dl) 8.7% NA NA Borderline to High 7.%.% ( mg/dl nd mg/dl to > mg/dl) 7.% NA NA Increse by mg/dl Fsting Totl Cholesterol Norml to High (<7 mg/dl to mg/dl) Borderline to High ( 7 mg/dl nd < mg/dl to mg/dl) Increse by mg/dl Fsting LDL Cholesterol Norml to High (< mg/dl to mg/dl) Borderline to High ( mg/dl nd < mg/dl to mg/dl) Not Applicble %.%.%.% 8.% 7.7% NA 78 NA NA.8% NA 7.7% NA 7.% NA %.%.%.% 8.% % NA NA NA.% NA.% NA 7.% NA Weight Gin Potentil consequences of weight gin should be considered prior to strting olnzpine. Ptients receiving olnzpine should receive regulr monitoring of weight [see Ptient Counseling Informtion (7.)]. Monotherpy in Adults In n nlysis of plcebo-controlled olnzpine monotherpy studies, olnzpine-treted ptients gined n verge of. kg (.7 lb) compred to n verge. kg (. lb) weight loss in plcebo-treted ptients with medin exposure of weeks;.% of olnzpine-treted ptients gined t lest 7% of their bseline weight, compred to % of plcebo-treted ptients, with medin exposure to event of 8 weeks;.% of olnzpine-treted ptients gined t lest % of their bseline weight, compred to.% of plcebo-treted ptients, with medin exposure to event of weeks. Cliniclly significnt weight gin ws observed cross ll bseline Body Mss Index (BMI) ctegories. Discontinution due to weight gin occurred in.% of olnzpine-treted ptients nd in % of plcebo-treted ptients. In long-term studies (t lest 8 weeks), the men weight gin ws. kg (. lb) (medin exposure of 7 dys, N=). The percentges of ptients who gined t lest 7%, %, or % of their bseline body weight with long-term exposure were %, %, nd %, respectively. Discontinution due to weight gin occurred in.% of olnzpinetreted ptients following t lest 8 weeks of exposure.

12 Tble includes dt on dult weight gin with olnzpine pooled from 8 clinicl trils. The dt in ech column represent dt for those ptients who completed tretment periods of the durtions specified. Amount Gined kg (lb) to (- lb) > to (- lb) > to (- lb) > to (- lb) > to (- lb) > to (- lb) > (> lb) Tble : Weight Gin with Use in Adults Weeks Months Months Months (N=7) (N=) (N=) (N=7) (%) (%) (%) (%) Months (N=7) (%) Dose group differences with respect to weight gin hve been observed. In single 8-week rndomized, doubleblind, fixed-dose study compring (N=), (N=) nd (N=) mg/dy of orl olnzpine in dult ptients with schizophreni or schizoffective disorder, men bseline to endpoint increse in weight ( mg/dy:. kg; mg/dy:. kg; mg/dy: kg) ws observed with significnt differences between vs mg/dy. Monotherpy in Adolescents The sfety nd efficcy of olnzpine hve not been estblished in ptients under the ge of yers. Men increse in weight in dolescents ws greter thn in dults. In plcebocontrolled trils, discontinution due to weight gin occurred in % of olnzpine-treted ptients, compred to % of plcebo-treted ptients. Tble 7: Weight Gin with Use in Adolescents from -Controlled Trils -treted ptients -treted ptients Men chnge in body weight from. kg (. lb). kg (.7 lb) bseline (medin exposure = weeks) Percentge of ptients who gined t.%.8% lest 7% of bseline body weight (medin exposure to 7% = weeks) (medin exposure to 7% = 8 weeks) Percentge of ptients who gined t 7.%.7% lest % of bseline body weight (medin exposure to % = weeks) (medin exposure to % = 8 weeks) In long-term studies (t lest weeks), the men weight gin ws. kg (. lb); (medin exposure of dys, N=7). The percentges of dolescents who gined t lest 7%, %, or % of their bseline body weight with long-term exposure were 8%, %, nd %, respectively. Among dolescent ptients, men weight gin by bseline BMI ctegory ws. kg (. lb),. kg (. lb), nd.7 kg (7. lb), respectively, for norml (N=), overweight (N=) nd obese (N=7). Discontinution due to weight gin occurred in.% of olnzpine-treted ptients following t lest weeks of exposure. Tble 8 shows dt on dolescent weight gin with olnzpine pooled from clinicl trils. The dt in ech column represent dt for those ptients who completed tretment periods of the durtions specified. Little clinicl tril dt is vilble on weight gin in dolescents with olnzpine beyond months of tretment. Tble 8: Weight Gin with Use in Adolescents Weeks Amount Gined (N=) kg (lb) (%). to (- lb) 7. > to (- lb). > to (- lb).8 > to (- lb).8 > to (- lb).8 > to (- lb) > to (-77 lb) > to (77-88 lb) > (>88 lb) Months (N=) (%)

13 Trdive Dyskinesi A syndrome of potentilly irreversible, involuntry, dyskinetic movements my develop in ptients treted with ntipsychotic drugs. Although the prevlence of the syndrome ppers to be highest mong the elderly, especilly elderly women, it is impossible to rely upon prevlence estimtes to predict, t the inception of ntipsychotic tretment, which ptients re likely to develop the syndrome. Whether ntipsychotic drug products differ in their potentil to cuse trdive dyskinesi is unknown. The risk of developing trdive dyskinesi nd the likelihood tht it will become irreversible re believed to increse s the durtion of tretment nd the totl cumultive dose of ntipsychotic drugs dministered to the ptient increse. However, the syndrome cn develop, lthough much less commonly, fter reltively brief tretment periods t low doses or my even rise fter discontinution of tretment. There is no known tretment for estblished cses of trdive dyskinesi, lthough the syndrome my remit, prtilly or completely, if ntipsychotic tretment is withdrwn. Antipsychotic tretment, itself, however, my suppress (or prtilly suppress) the signs nd symptoms of the syndrome nd thereby my possibly msk the underlying process. The effect tht symptomtic suppression hs upon the long-term course of the syndrome is unknown. Given these considertions, olnzpine should be prescribed in mnner tht is most likely to minimize the occurrence of trdive dyskinesi. Chronic ntipsychotic tretment should generlly be reserved for ptients () who suffer from chronic illness tht is known to respond to ntipsychotic drugs, nd () for whom lterntive, eqully effective, but potentilly less hrmful tretments re not vilble or pproprite. In ptients who do require chronic tretment, the smllest dose nd the shortest durtion of tretment producing stisfctory clinicl response should be sought. The need for continued tretment should be ressessed periodiclly. If signs nd symptoms of trdive dyskinesi pper in ptient on olnzpine, drug discontinution should be considered. However, some ptients my require tretment with olnzpine despite the presence of the syndrome. For specific informtion bout the wrnings of lithium or vlprote, refer to the Wrnings section of the pckge inserts for these other products.. Orthosttic Hypotension my induce orthosttic hypotension ssocited with dizziness, tchycrdi, brdycrdi nd, in some ptients, syncope, especilly during the initil dose-titrtion period, probbly reflecting its α-drenergic ntgonistic properties [see Ptient Counseling Informtion (7.7)]. For orl olnzpine therpy, the risk of orthosttic hypotension nd syncope my be minimized by inititing therpy with mg QD [see Dosge nd Administrtion ()]. A more grdul titrtion to the trget dose should be considered if hypotension occurs. Hypotension, brdycrdi with or without hypotension, tchycrdi, nd syncope were lso reported during the clinicl trils with intrmusculr olnzpine for injection. In n open-lbel clinicl phrmcology study in nongitted ptients with schizophreni in which the sfety nd tolerbility of intrmusculr olnzpine were evluted under mximl dosing regimen (three mg doses dministered hours prt), pproximtely one-third of these ptients experienced significnt orthosttic decrese in systolic blood pressure (i.e., decrese mmhg) [see Dosge nd Administrtion (.)]. Syncope ws reported in.% (/) of olnzpine-treted ptients in phse - orl olnzpine studies nd in.% (/7) of olnzpine-treted ptients with gittion in the intrmusculr olnzpine for injection studies. Three norml volunteers in phse studies with intrmusculr olnzpine experienced hypotension, brdycrdi, nd sinus puses of up to seconds tht spontneously resolved (in cses the rections occurred on intrmusculr olnzpine, nd in cse, on orl olnzpine). The risk for this sequence of hypotension, brdycrdi, nd sinus puse my be greter in nonpsychitric ptients compred to psychitric ptients who re possibly more dpted to certin effects of psychotropic drugs. For intrmusculr olnzpine for injection therpy, ptients should remin recumbent if drowsy or dizzy fter injection until exmintion hs indicted tht they re not experiencing posturl hypotension, brdycrdi, nd/or hypoventiltion. should be used with prticulr cution in ptients with known crdiovsculr disese (history of myocrdil infrction or ischemi, hert filure, or conduction bnormlities), cerebrovsculr disese, nd conditions which would predispose ptients to hypotension (dehydrtion, hypovolemi, nd tretment with ntihypertensive medictions) where the occurrence of syncope, or hypotension nd/or brdycrdi might put the ptient t incresed medicl risk. Cution is necessry in ptients who receive tretment with other drugs hving effects tht cn induce hypotension, brdycrdi, respirtory or centrl nervous system depression [see Drug Interctions (7)]. Concomitnt dministrtion of intrmusculr olnzpine nd prenterl benzodizepine is not recommended due to the potentil for excessive sedtion nd crdiorespirtory depression..7 Leukopeni, Neutropeni, nd Agrnulocytosis Clss Effect In clinicl tril nd/or postmrketing experience, events of leukopeni/neutropeni hve been reported temporlly relted to ntipsychotic gents, including ZYPREXA. Agrnulocytosis hs lso been reported. Possible risk fctors for leukopeni/neutropeni include pre-existing low white blood cell count (WBC) nd history of drug induced leukopeni/neutropeni. Ptients with history of cliniclly significnt low WBC or drug induced leukopeni/neutropeni should hve their complete blood count (CBC) monitored frequently during the first few months of.

14 therpy nd discontinution of ZYPREXA should be considered t the first sign of cliniclly significnt decline in WBC in the bsence of other custive fctors. Ptients with cliniclly significnt neutropeni should be crefully monitored for fever or other symptoms or signs of infection nd treted promptly if such symptoms or signs occur. Ptients with severe neutropeni (bsolute neutrophil count </mm) should discontinue ZYPREXA nd hve their WBC followed until recovery..8 Dysphgi Esophgel dysmotility nd spirtion hve been ssocited with ntipsychotic drug use. Aspirtion pneumoni is common cuse of morbidity nd mortlity in ptients with dvnced Alzheimer s disese. is not pproved for the tretment of ptients with Alzheimer s disese.. Seizures During premrketing testing, seizures occurred in.% (/) of olnzpine-treted ptients. There were confounding fctors tht my hve contributed to the occurrence of seizures in mny of these cses. should be used cutiously in ptients with history of seizures or with conditions tht potentilly lower the seizure threshold, e.g., Alzheimer s dementi. is not pproved for the tretment of ptients with Alzheimer s disese. Conditions tht lower the seizure threshold my be more prevlent in popultion of yers or older.. Potentil for Cognitive nd Motor Impirment Somnolence ws commonly reported dverse rection ssocited with olnzpine tretment, occurring t n incidence of % in olnzpine ptients compred to % in plcebo ptients. This dverse rection ws lso dose relted. Somnolence led to discontinution in.% (/) of ptients in the premrketing dtbse. Since olnzpine hs the potentil to impir judgment, thinking, or motor skills, ptients should be cutioned bout operting hzrdous mchinery, including utomobiles, until they re resonbly certin tht olnzpine therpy does not ffect them dversely [see Ptient Counseling Informtion (7.8)].. Body Temperture Regultion Disruption of the body s bility to reduce core body temperture hs been ttributed to ntipsychotic gents. Approprite cre is dvised when prescribing olnzpine for ptients who will be experiencing conditions which my contribute to n elevtion in core body temperture, e.g., exercising strenuously, exposure to extreme het, receiving concomitnt mediction with nticholinergic ctivity, or being subject to dehydrtion [see Ptient Counseling Informtion (7.)].. Use in Ptients with Concomitnt Illness Clinicl experience with olnzpine in ptients with certin concomitnt systemic illnesses is limited [see Clinicl Phrmcology (.)]. exhibits in vitro muscrinic receptor ffinity. In premrketing clinicl trils with olnzpine, olnzpine ws ssocited with constiption, dry mouth, nd tchycrdi, ll dverse rections possibly relted to cholinergic ntgonism. Such dverse rections were not often the bsis for discontinutions from olnzpine, but olnzpine should be used with cution in ptients with cliniclly significnt prosttic hypertrophy, nrrow ngle glucom, or history of prlytic ileus or relted conditions. In plcebo-controlled studies of olnzpine in elderly ptients with dementi-relted psychosis (n=8), the following tretment-emergent dverse rections were reported in olnzpine-treted ptients t n incidence of t lest % nd significntly greter thn plcebo-treted ptients: flls, somnolence, peripherl edem, bnorml git, urinry incontinence, lethrgy, incresed weight, stheni, pyrexi, pneumoni, dry mouth nd visul hllucintions. The rte of discontinution due to dverse rections ws greter with olnzpine thn plcebo (% vs 7%). Elderly ptients with dementi-relted psychosis treted with olnzpine re t n incresed risk of deth compred to plcebo. is not pproved for the tretment of ptients with dementi-relted psychosis [see Boxed Wrning, Wrnings nd Precutions (.), nd Ptient Counseling Informtion (7.)]. hs not been evluted or used to ny pprecible extent in ptients with recent history of myocrdil infrction or unstble hert disese. Ptients with these dignoses were excluded from premrketing clinicl studies. Becuse of the risk of orthosttic hypotension with olnzpine, cution should be observed in crdic ptients [see Wrnings nd Precutions (.)].. Hyperprolctinemi As with other drugs tht ntgonize dopmine D receptors, olnzpine elevtes prolctin levels, nd the elevtion persists during chronic dministrtion. Hyperprolctinemi my suppress hypothlmic GnRH, resulting in reduced pituitry gondotropin secretion. This, in turn, my inhibit reproductive function by impiring gondl steroidogenesis in both femle nd mle ptients. Glctorrhe, menorrhe, gynecomsti, nd impotence hve been reported in ptients receiving prolctin-elevting compounds. Long-stnding hyperprolctinemi when ssocited with hypogondism my led to decresed bone density in both femle nd mle subjects. Tissue culture experiments indicte tht pproximtely one-third of humn brest cncers re prolctin dependent in vitro, fctor of potentil importnce if the prescription of these drugs is contemplted in ptient with previously detected brest cncer. As is common with compounds which increse prolctin relese, n increse in mmmry glnd neoplsi ws observed in the olnzpine crcinogenicity studies conducted in mice nd rts [see Nonclinicl Toxicology (.)]. Neither clinicl studies nor epidemiologic studies conducted to dte hve shown n ssocition between chronic

15 dministrtion of this clss of drugs nd tumorigenesis in humns; the vilble evidence is considered too limited to be conclusive t this time. In plcebo-controlled olnzpine clinicl studies (up to weeks), chnges from norml to high in prolctin concentrtions were observed in % of dults treted with olnzpine s compred to.% of dults treted with plcebo. In pooled nlysis from clinicl studies including 8 dults treted with olnzpine, potentilly ssocited clinicl mnifesttions included menstrul-relted events (% [/] of femles), sexul function-relted events (% [/8] of femles nd mles), nd brest-relted events (.7% [/] of femles,.% [/8] of mles). In plcebo-controlled olnzpine monotherpy studies in dolescent ptients (up to weeks) with schizophreni or bipolr I disorder (mnic or mixed episodes), chnges from norml to high in prolctin concentrtions were observed in 7% of olnzpine-treted ptients compred to 7% of plcebo-treted ptients. In pooled nlysis from clinicl trils including dolescents treted with olnzpine, potentilly ssocited clinicl mnifesttions included menstrulrelted events (% [/8] of femles), sexul function-relted events (.7% [/] of femles nd mles), nd brestrelted events (% [/8] of femles, % [7/8] of mles) [see Use in Specific Popultions (8.)]. Bsed on serch of the following terms: menorrhe, hypomenorrhe, menstrution delyed, nd oligomenorrhe. Bsed on serch of the following terms: norgsmi, delyed ejcultion, erectile dysfunction, decresed libido, loss of libido, bnorml orgsm, nd sexul dysfunction. Bsed on serch of the following terms: brest dischrge, enlrgement or swelling, glctorrhe, gynecomsti, nd lcttion disorder. Dose group differences with respect to prolctin elevtion hve been observed. In single 8-week rndomized, double-blind, fixed-dose study compring (N=), (N=) nd (N=) mg/dy of orl olnzpine in dult ptients with schizophreni or schizoffective disorder, incidence of prolctin elevtion >. ng/ml (femle) or >8.77 ng/ml (mle) t ny time during the tril ( mg/dy:.%; mg/dy:.7%; mg/dy:.%) indicted significnt differences between vs mg/dy nd vs mg/dy.. Use in Combintion with Fluoxetine, Lithium, or Vlprote When using ZYPREXA nd fluoxetine in combintion, the prescriber should lso refer to the Wrnings nd Precutions section of the pckge insert for Symbyx. When using ZYPREXA in combintion with lithium or vlprote, the prescriber should refer to the Wrnings nd Precutions sections of the pckge inserts for lithium or vlprote [see Drug Interctions (7)].. Lbortory Tests Fsting blood glucose testing nd lipid profile t the beginning of, nd periodiclly during, tretment is recommended [see Wrnings nd Precutions (.) nd Ptient Counseling Informtion (7., 7.)]. ADVERSE REACTIONS When using ZYPREXA nd fluoxetine in combintion, lso refer to the Adverse Rections section of the pckge insert for Symbyx.. Clinicl Trils Experience Becuse clinicl trils re conducted under widely vrying conditions, dverse rection rtes observed in the clinicl trils of drug cnnot be directly compred to rtes in the clinicl trils of nother drug nd my not reflect or predict the rtes observed in prctice. Clinicl Trils in Adults The informtion below for olnzpine is derived from clinicl tril dtbse for olnzpine consisting of 8 dult ptients with pproximtely ptient-yers of exposure to orl olnzpine nd 7 ptients with exposure to intrmusculr olnzpine for injection. This dtbse includes: () ptients who prticipted in multiple-dose orl olnzpine premrketing trils in schizophreni nd Alzheimer s disese representing pproximtely ptient-yers of exposure s of Februry, ; () 8 ptients who prticipted in orl olnzpine premrketing bipolr I disorder (mnic or mixed episodes) trils representing pproximtely ptient-yers of exposure; () ptients who prticipted in n orl olnzpine tril of ptients hving vrious psychitric symptoms in ssocition with Alzheimer s disese representing pproximtely ptient-yers of exposure; () 788 ptients from 88 dditionl orl olnzpine clinicl trils s of December, ; nd () 7 ptients who prticipted in intrmusculr olnzpine for injection premrketing trils in gitted ptients with schizophreni, bipolr I disorder (mnic or mixed episodes), or dementi. In ddition, informtion from the premrketing -week clinicl study dtbse for olnzpine in combintion with lithium or vlprote, consisting of ptients who prticipted in bipolr I disorder (mnic or mixed episodes) trils with pproximtely ptient-yers of exposure, is included below. The conditions nd durtion of tretment with olnzpine vried gretly nd included (in overlpping ctegories) open-lbel nd double-blind phses of studies, inptients nd outptients, fixed-dose nd dose-titrtion studies, nd short-term or longer-term exposure. Adverse rections were ssessed by collecting dverse rections, results of physicl exmintions, vitl signs, weights, lbortory nlytes, ECGs, chest x-rys, nd results of ophthlmologic exmintions. Certin portions of the discussion below relting to objective or numeric sfety prmeters, nmely, dosedependent dverse rections, vitl sign chnges, weight gin, lbortory chnges, nd ECG chnges re derived from

16 studies in ptients with schizophreni nd hve not been duplicted for bipolr I disorder (mnic or mixed episodes) or gittion. However, this informtion is lso generlly pplicble to bipolr I disorder (mnic or mixed episodes) nd gittion. Adverse rections during exposure were obtined by spontneous report nd recorded by clinicl investigtors using terminology of their own choosing. Consequently, it is not possible to provide meningful estimte of the proportion of individuls experiencing dverse rections without first grouping similr types of rections into smller number of stndrdized rection ctegories. In the tbles nd tbultions tht follow, MedDRA nd COSTART Dictionry terminology hs been used to clssify reported dverse rections. The stted frequencies of dverse rections represent the proportion of individuls who experienced, t lest once, tretment-emergent dverse rection of the type listed. A rection ws considered tretment emergent if it occurred for the first time or worsened while receiving therpy following bseline evlution. The reported rections do not include those rection terms tht were so generl s to be uninformtive. Rections listed elsewhere in lbeling my not be repeted below. It is importnt to emphsize tht, lthough the rections occurred during tretment with olnzpine, they were not necessrily cused by it. The entire lbel should be red to gin complete understnding of the sfety profile of olnzpine. The prescriber should be wre tht the figures in the tbles nd tbultions cnnot be used to predict the incidence of side effects in the course of usul medicl prctice where ptient chrcteristics nd other fctors differ from those tht previled in the clinicl trils. Similrly, the cited frequencies cnnot be compred with figures obtined from other clinicl investigtions involving different tretments, uses, nd investigtors. The cited figures, however, do provide the prescribing physicin with some bsis for estimting the reltive contribution of drug nd nondrug fctors to the dverse rections incidence in the popultion studied. Incidence of Adverse Rections in Short-Term, -Controlled nd Combintion Trils The following findings re bsed on premrketing trils of () orl olnzpine for schizophreni, bipolr I disorder (mnic or mixed episodes), subsequent tril of ptients hving vrious psychitric symptoms in ssocition with Alzheimer s disese, nd premrketing combintion trils, nd () intrmusculr olnzpine for injection in gitted ptients with schizophreni or bipolr I mni. Adverse Rections Associted with Discontinution of Tretment in Short-Term, -Controlled Trils Schizophreni Overll, there ws no difference in the incidence of discontinution due to dverse rections (% for orl olnzpine vs % for plcebo). However, discontinutions due to increses in ALT were considered to be drug relted (% for orl olnzpine vs % for plcebo). Bipolr I Disorder (Mnic or Mixed Episodes) Monotherpy Overll, there ws no difference in the incidence of discontinution due to dverse rections (% for orl olnzpine vs % for plcebo). Agittion Overll, there ws no difference in the incidence of discontinution due to dverse rections (.% for intrmusculr olnzpine for injection vs % for plcebo). Adverse Rections Associted with Discontinution of Tretment in Short-Term Combintion Trils Bipolr I Disorder (Mnic or Mixed Episodes), s Adjunct to Lithium or Vlprote In study of ptients who were lredy tolerting either lithium or vlprote s monotherpy, discontinution rtes due to dverse rections were % for the combintion of orl olnzpine with lithium or vlprote compred to % for ptients who remined on lithium or vlprote monotherpy. Discontinutions with the combintion of orl olnzpine nd lithium or vlprote tht occurred in more thn ptient were: somnolence (%), weight gin (%), nd peripherl edem (%). Commonly Observed Adverse Rections in Short-Term, -Controlled Trils The most commonly observed dverse rections ssocited with the use of orl olnzpine (incidence of % or greter) nd not observed t n equivlent incidence mong plcebo-treted ptients (olnzpine incidence t lest twice tht for plcebo) were: Tble : Common Tretment-Emergent Adverse Rections Associted with the Use of Orl in -Week Trils SCHIZOPHRENIA Percentge of Ptients Reporting Event Adverse Rection (N=8) (N=8) Posturl hypotension Constiption Weight gin Dizziness Personlity disorder 8 Akthisi Personlity disorder is the COSTART term for designting nonggressive objectionble behvior.

17 7 Tble : Common Tretment-Emergent Adverse Rections Associted with the Use of Orl in -Week nd -Week Trils Bipolr I Disorder (Mnic or Mixed Episodes) Percentge of Ptients Reporting Event Adverse Rection (N=) (N=) Astheni Dry mouth 7 Constiption Dyspepsi Incresed ppetite Somnolence Dizziness 8 Tremor Intrmusculr There ws dverse rection (somnolence) observed t n incidence of % or greter mong intrmusculr olnzpine for injection-treted ptients nd not observed t n equivlent incidence mong plcebo-treted ptients (olnzpine incidence t lest twice tht for plcebo) during the plcebo-controlled premrketing studies. The incidence of somnolence during the hour IM tretment period in clinicl trils in gitted ptients with schizophreni or bipolr I mni ws % for intrmusculr olnzpine for injection nd % for plcebo. Adverse Rections Occurring t n Incidence of % or More mong Orl -Treted Ptients in ShortTerm, -Controlled Trils Tble enumertes the incidence, rounded to the nerest percent, of tretment-emergent dverse rections tht occurred in % or more of ptients treted with orl olnzpine (doses. mg/dy) nd with incidence greter thn plcebo who prticipted in the cute phse of plcebo-controlled trils. Tble : Tretment-Emergent Adverse Rections: Incidence in Short-Term, -Controlled Clinicl Trils with Orl Percentge of Ptients Reporting Event Body System/Adverse Rection (N=) (N=) Body s Whole Accidentl injury 8 Astheni Fever Bck pin Chest pin Crdiovsculr System Posturl hypotension Tchycrdi Hypertension Digestive System Dry mouth Constiption Dyspepsi 7 Vomiting Incresed ppetite Hemic nd Lymphtic System Ecchymosis Metbolic nd Nutritionl Disorders Weight gin Peripherl edem Musculoskeletl System Extremity pin (other thn joint) Joint pin Nervous System Somnolence Insomni Dizziness

18 8 Abnorml git Tremor Akthisi Hypertoni Articultion impirment Respirtory System Rhinitis Cough incresed Phryngitis Specil Senses Amblyopi Urogenitl System Urinry incontinence Urinry trct infection 7 Dose Dependency of Adverse Rections A dose group difference hs been observed for ftigue, dizziness, weight gin nd prolctin elevtion. In single 8-week rndomized, double-blind, fixed-dose study compring (N=), (N=) nd (N=) mg/dy of orl olnzpine in dult ptients with schizophreni or schizoffective disorder, incidence of ftigue ( mg/dy:.%; mg/dy:.%; mg/dy:.%) ws observed with significnt differences between vs nd vs mg/dy. The incidence of dizziness ( mg/dy:.%; mg/dy:.%; mg/dy:.%) ws observed with significnt differences between vs mg. Dose group differences were lso noted for weight gin nd prolctin elevtion [see Wrnings nd Precutions (.,.)]. The following tble ddresses dose reltedness for other dverse rections using dt from schizophreni tril involving fixed dosge rnges of orl olnzpine. It enumertes the percentge of ptients with tretment-emergent dverse rections for the fixed-dose rnge groups nd plcebo. The dt were nlyzed using the Cochrn-Armitge test, excluding the plcebo group, nd the tble includes only those dverse rections for which there ws trend. Tble : Percentge of Ptients from Schizophreni Tril with Tretment-Emergent Adverse Rections for the Dose Rnge Groups nd Percentge of Ptients Reporting Event ±. mg/dy ±. mg/dy ±. mg/dy Adverse Rection (N=8) (N=) (N=) (N=) Astheni 8 Dry mouth Nuse Somnolence Tremor 7 Commonly Observed Adverse Rections in Short-Term Trils of Orl s Adjunct to Lithium or Vlprote In the bipolr I disorder (mnic or mixed episodes) djunct plcebo-controlled trils, the most commonly observed dverse rections ssocited with the combintion of olnzpine nd lithium or vlprote (incidence of % nd t lest twice plcebo) were: Tble : Common Tretment-Emergent Adverse Rections Associted with the Use of Orl in -Week Adjunct to Lithium or Vlprote Trils Bipolr I Disorder (Mnic or Mixed Episodes) Percentge of Ptients Reporting Event with with lithium or vlprote lithium or vlprote Adverse Rection (N=) (N=) Dry mouth Weight gin 7 Incresed ppetite 8 Dizziness 7 Bck pin 8 Constiption 8

19 Speech disorder Incresed slivtion Amnesi Presthesi 7 Adverse Rections Occurring t n Incidence of % or More mong Orl -Treted Ptients in ShortTerm Trils of s Adjunct to Lithium or Vlprote Tble enumertes the incidence, rounded to the nerest percent, of tretment-emergent dverse rections tht occurred in % or more of ptients treted with the combintion of olnzpine (doses mg/dy) nd lithium or vlprote nd with incidence greter thn lithium or vlprote lone who prticipted in the cute phse of plcebo-controlled combintion trils. Tble : Tretment-Emergent Adverse Rections: Incidence in Short-Term, -Controlled Clinicl Trils of Orl s Adjunct to Lithium or Vlprote Percentge of Ptients Reporting Event with with lithium or vlprote lithium or vlprote Body System/Adverse Rection (N=) (N=) Body s Whole Astheni 8 Bck pin 8 Accidentl injury Chest pin Crdiovsculr System Hypertension Digestive System Dry mouth Incresed ppetite 8 Thirst Constiption 8 Incresed slivtion Metbolic nd Nutritionl Disorders Weight gin 7 Peripherl edem Edem Nervous System Somnolence 7 Tremor Depression 8 7 Dizziness 7 Speech disorder 7 Amnesi Presthesi Apthy Confusion Euphori Incoordintion Respirtory System Phryngitis Dyspne Skin nd Appendges Sweting Acne Dry skin Specil Senses Amblyopi Abnorml vision Urogenitl System Dysmenorrhe Vginitis

20 Denomintor used ws for femles only (olnzpine, N=8; plcebo, N=). For specific informtion bout the dverse rections observed with lithium or vlprote, refer to the Adverse Rections section of the pckge inserts for these other products. Adverse Rections Occurring t n Incidence of % or More mong Intrmusculr for InjectionTreted Ptients in Short-Term, -Controlled Trils Tble enumertes the incidence, rounded to the nerest percent, of tretment-emergent dverse rections tht occurred in % or more of ptients treted with intrmusculr olnzpine for injection (dose rnge of.- mg/injection) nd with incidence greter thn plcebo who prticipted in the short-term, plcebo-controlled trils in gitted ptients with schizophreni or bipolr I mni. Tble : Tretment-Emergent Adverse Rections: Incidence in Short-Term ( Hour), -Controlled Clinicl Trils with Intrmusculr for Injection in Agitted Ptients with Schizophreni or Bipolr I Mni Percentge of Ptients Reporting Event Body System/Adverse Rection (N=) (N=) Body s Whole Astheni Crdiovsculr System Hypotension Posturl hypotension Nervous System Somnolence Dizziness Tremor. Extrpyrmidl Symptoms The following tble enumertes the percentge of ptients with tretment-emergent extrpyrmidl symptoms s ssessed by ctegoricl nlyses of forml rting scles during cute therpy in controlled clinicl tril compring orl olnzpine t fixed doses with plcebo in the tretment of schizophreni in -week tril. Tble : Tretment-Emergent Extrpyrmidl Symptoms Assessed by Rting Scles Incidence in Fixed Dosge Rnge, -Controlled Clinicl Tril of Orl in Schizophreni Acute Phse Percentge of Ptients Reporting Event ±. mg/dy ±. mg/dy ±. mg/dy Prkinsonism b Akthisi 7 Percentge of ptients with Simpson-Angus Scle totl score >. b Percentge of ptients with Brnes Akthisi Scle globl score. The following tble enumertes the percentge of ptients with tretment-emergent extrpyrmidl symptoms s ssessed by spontneously reported dverse rections during cute therpy in the sme controlled clinicl tril compring olnzpine t fixed doses with plcebo in the tretment of schizophreni in -week tril. Tble 7: Tretment-Emergent Extrpyrmidl Symptoms Assessed by Adverse Rections Incidence in Fixed Dosge Rnge, -Controlled Clinicl Tril of Orl in Schizophreni Acute Phse Percentge of Ptients Reporting Event ±. mg/dy ±. mg/dy ±. mg/dy (N=8) (N=) (N=) (N=) Dystonic events b Prkinsonism events 8 c Akthisi events d Dyskinetic events e Residul events Any extrpyrmidl event

Target: 10 mg/day within several days Schizophrenia in adolescents (2.1)

Target: 10 mg/day within several days Schizophrenia in adolescents (2.1) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ZYPREXA sfely nd effectively. See full prescribing informtion for ZYPREXA. ZYPREXA (olnzpine) Tblet

More information

Known CYP2D6 Poor Metabolizers

Known CYP2D6 Poor Metabolizers HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ABILIFY sfely nd effectively. See full prescribing informtion for ABILIFY. Tblets ABILIFY DISCMELT

More information

INITIATION OF THERAPY Patient-specific considerations for initiation of apixaban therapy include the following:

INITIATION OF THERAPY Patient-specific considerations for initiation of apixaban therapy include the following: UNC HEALTH CARE GUIDELINE Mngement of Apixn in Adults Apixn (Eliquis ) is n orl nticogulnt tht cts s fctor X inhiitor. It is pproved y the FDA for the prevention of stroke nd systemic emolism in ptients

More information

TABLE 1. Initial Rivaroxaban Dosing Indication Renal Function a (CrCL ml/min) Recommended Dose b

TABLE 1. Initial Rivaroxaban Dosing Indication Renal Function a (CrCL ml/min) Recommended Dose b U N C H E A L T H C A R E G U I D E L I N E Mngement of Rivroxn in Adults Rivroxn (Xrelto ) is n orl nticogulnt tht cts s fctor X inhiitor. It is pproved y the FDA s n lterntive to wrfrin for the prevention

More information

INITIATION OF THERAPY Patient-specific considerations for initiation of rivaroxaban therapy include the following:

INITIATION OF THERAPY Patient-specific considerations for initiation of rivaroxaban therapy include the following: UNC HEALTH CARE GUIDELINE Mngement of Rivroxn in Adults Rivroxn (Xrelto ) is n orl nticogulnt tht cts s fctor X inhiitor. It is pproved y the FDA for the following indictions: Prevention of stroke nd systemic

More information

Reversing Medications That Cause Bleeding

Reversing Medications That Cause Bleeding Reversing Medictions Tht Cuse Bleeding Dine M. Birnbumer, M.D., FACEP Professor of Medicine University of Cliforni, Los Angeles Senior Fculty Deprtment of Emergency Medicine Hrbor-UCLA Medicl Center The

More information

Warnings and Precautions Never Share a Humalog KwikPen, Cartridge, Reusable Pen Compatible with Lilly 3 ml Cartridges, or Syringe Between

Warnings and Precautions Never Share a Humalog KwikPen, Cartridge, Reusable Pen Compatible with Lilly 3 ml Cartridges, or Syringe Between 1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use HUMALOG sfely nd effectively. See full prescriing informtion for HUMALOG. HUMALOG (insulin lispro

More information

BOTOX (onabotulinumtoxina) treatment record for Chronic Migraine patients

BOTOX (onabotulinumtoxina) treatment record for Chronic Migraine patients (onbotulinumtoxina) tretment record for Chronic Migrine ptients for injection is indicted for the prophylxis of hedches in dult ptients with chronic migrine ( 15 dys per month with hedche lsting 4 hours

More information

Utilization of Smoking Cessation Benefits in Medicaid Managed Care, 2009-2013

Utilization of Smoking Cessation Benefits in Medicaid Managed Care, 2009-2013 Utiliztion of Smoking Cesstion Benefits in Medicid Mnged Cre, 2009-2013 Office of Qulity nd Ptient Sfety New York Stte Deprtment of Helth Jnury 2015 Introduction According to the New York Stte Tocco Control

More information

EXPERIMENTAL AND THERAPEUTIC MEDICINE 8: 1191-1196, 2014

EXPERIMENTAL AND THERAPEUTIC MEDICINE 8: 1191-1196, 2014 EXPERIMENTAL AND THERAPEUTIC MEDICINE 8: 1191-1196, 2014 Comprison of continuous subcutneous insulin infusion nd insulin glrgine-bsed multiple dily insulin sprt injections with preferentil djustment of

More information

See 17 for PATIENT COUNSELING INFORMATION. Revised: 11/2013

See 17 for PATIENT COUNSELING INFORMATION. Revised: 11/2013 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use BOOSTRIX sfely nd effectively. See full prescribing informtion for BOOSTRIX. BOOSTRIX (Tetnus Toxoid,

More information

Epilepsy & Behavior 15 (2009) 56 65. Contents lists available at ScienceDirect. Epilepsy & Behavior. journal homepage: www.elsevier.

Epilepsy & Behavior 15 (2009) 56 65. Contents lists available at ScienceDirect. Epilepsy & Behavior. journal homepage: www.elsevier. Epilepsy & Behvior 15 (2009) 56 65 Contents lists vilble t ScienceDirect Epilepsy & Behvior journl homepge: www.elsevier.com/locte/yebeh Drug tretment of epilepsy: Options nd limittions Dieter Schmidt

More information

DlNBVRGH + Sickness Absence Monitoring Report. Executive of the Council. Purpose of report

DlNBVRGH + Sickness Absence Monitoring Report. Executive of the Council. Purpose of report DlNBVRGH + + THE CITY OF EDINBURGH COUNCIL Sickness Absence Monitoring Report Executive of the Council 8fh My 4 I.I...3 Purpose of report This report quntifies the mount of working time lost s result of

More information

Objective: Erectile dysfunction and depression are highly associated. Previous studies have shown benefits of phosphodiesterase-5

Objective: Erectile dysfunction and depression are highly associated. Previous studies have shown benefits of phosphodiesterase-5 Article Efficcy nd Tolerbility of Vrdenfil in Men With Mild Depression nd Erectile Dysfunction: The Depression-Relted Improvement With Vrdenfil for Erectile Response Study Rymond Rosen, Ph.D. Ridwn Shbsigh,

More information

Malignant Pleural Mesothelioma (MPM) treatment with ALIMTA therapy

Malignant Pleural Mesothelioma (MPM) treatment with ALIMTA therapy YOUR LIFE. Mlignnt Pleurl Mesotheliom (MPM) tretment with ALIMTA therpy ALIMTA is tretment for mlignnt pleurl mesotheliom (MPM), which is cncer tht ffects the inside lining of the chest cvity. ALIMTA is

More information

Active & Retiree Plan: Trustees of the Milwaukee Roofers Health Fund Coverage Period: 06/01/2015-05/31/2016 Summary of Benefits and Coverage:

Active & Retiree Plan: Trustees of the Milwaukee Roofers Health Fund Coverage Period: 06/01/2015-05/31/2016 Summary of Benefits and Coverage: Summry of Benefits nd Coverge: Wht this Pln Covers & Wht it Costs Coverge for: Single & Fmily Pln Type: NPOS This is only summry. If you wnt more detil bout your coverge nd costs, you cn get the complete

More information

Treatment Spring Late Summer Fall 0.10 5.56 3.85 0.61 6.97 3.01 1.91 3.01 2.13 2.99 5.33 2.50 1.06 3.53 6.10 Mean = 1.33 Mean = 4.88 Mean = 3.

Treatment Spring Late Summer Fall 0.10 5.56 3.85 0.61 6.97 3.01 1.91 3.01 2.13 2.99 5.33 2.50 1.06 3.53 6.10 Mean = 1.33 Mean = 4.88 Mean = 3. The nlysis of vrince (ANOVA) Although the t-test is one of the most commonly used sttisticl hypothesis tests, it hs limittions. The mjor limittion is tht the t-test cn be used to compre the mens of only

More information

Antipsychotic Medication Use Among Children and Risk of Diabetes Mellitus

Antipsychotic Medication Use Among Children and Risk of Diabetes Mellitus Antipsychotic Mediction Use Among Children nd Risk of Dibetes Mellitus AUTHORS: Susn E. Andrde, ScD, Jon C. Lo, MD, b Dougls Roblin, PhD, c Hssn Fouyzi, MS, Dniel F. Connor, MD, d Robert B. Penfold, PhD,

More information

Health insurance exchanges What to expect in 2014

Health insurance exchanges What to expect in 2014 Helth insurnce exchnges Wht to expect in 2014 33096CAEENABC 02/13 The bsics of exchnges As prt of the Affordble Cre Act (ACA or helth cre reform lw), strting in 2014 ALL Americns must hve minimum mount

More information

Health insurance marketplace What to expect in 2014

Health insurance marketplace What to expect in 2014 Helth insurnce mrketplce Wht to expect in 2014 33096VAEENBVA 06/13 The bsics of the mrketplce As prt of the Affordble Cre Act (ACA or helth cre reform lw), strting in 2014 ALL Americns must hve minimum

More information

Humana Critical Illness/Cancer

Humana Critical Illness/Cancer Humn Criticl Illness/Cncer Criticl illness/cncer voluntry coverges py benefits however you wnt With our criticl illness nd cncer plns, you'll receive benefit fter serious illness or condition such s hert

More information

ClearPeaks Customer Care Guide. Business as Usual (BaU) Services Peace of mind for your BI Investment

ClearPeaks Customer Care Guide. Business as Usual (BaU) Services Peace of mind for your BI Investment ClerPeks Customer Cre Guide Business s Usul (BU) Services Pece of mind for your BI Investment ClerPeks Customer Cre Business s Usul Services Tble of Contents 1. Overview...3 Benefits of Choosing ClerPeks

More information

Anthem Blue Cross Life and Health Insurance Company University of Southern California Custom Premier PPO 800/20%/20%

Anthem Blue Cross Life and Health Insurance Company University of Southern California Custom Premier PPO 800/20%/20% Anthem Blue Cross Life nd Helth Insurnce Compny University of Southern Cliforni Custom Premier 800/20%/20% Summry of Benefits nd Coverge: Wht this Pln Covers & Wht it Costs Coverge Period: 01/01/2015-12/31/2015

More information

National Diabetes Audit. Report 1: Care Processes and Treatment Targets

National Diabetes Audit. Report 1: Care Processes and Treatment Targets Ntionl Dibetes Audit 2011 2012 Report 1: Cre Processes nd Tretment Trgets The Ntionl Dibetes Audit is commissioned by The Helthcre Qulity Improvement Prtnership (HQIP) promotes qulity in helthcre. HQIP

More information

Many national organizations

Many national organizations SYMPOSIUM Primry-cre setting Implementtion of drug therpy monitoring clinic in primry-cre setting JILLMARIE K. YANCHICK Mny ntionl orgniztions hve identified the optiml mngement of chronic disese sttes

More information

The sickle cell diseases (SCDs) affect approximately

The sickle cell diseases (SCDs) affect approximately o r i g i n l c o m m u n i c t i o n Pin Mngement in Adults With Sickle Cell Disese in Medicl Center Emergency Deprtment Lwrence R. Solomon, MD Previous Presenttion: This pper ws presented in prt in bstrct

More information

ADVATE [Antihemophilic Factor (Recombinant)] Lyophilized Powder for Reconstitution for Intravenous Injection Initial U.S.

ADVATE [Antihemophilic Factor (Recombinant)] Lyophilized Powder for Reconstitution for Intravenous Injection Initial U.S. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ADVATE sfely nd effectively. See full prescribing informtion for ADVATE. ADVATE [Antihemophilic Fctor

More information

Improvements in glycemic control

Improvements in glycemic control CLINICAL report Ptient stisfction nd costs ssocited with insulin dministered by pen device or syringe during hospitliztion Improvements in glycemic control hve been shown to gretly reduce the progression

More information

AJP in Advance. Published May 2, 2011 (doi: 10.1176/appi.ajp.2011.10111645) Article

AJP in Advance. Published May 2, 2011 (doi: 10.1176/appi.ajp.2011.10111645) Article AJP in Advnce. Published My 2, 2011 (doi: 10.1176/ppi.jp.2011.10111645) Article Combining Medictions to Enhnce Depression Outcomes (CO-MED): Acute nd Long-Term Outcomes of Single-Blind Rndomized Study

More information

Small Businesses Decisions to Offer Health Insurance to Employees

Small Businesses Decisions to Offer Health Insurance to Employees Smll Businesses Decisions to Offer Helth Insurnce to Employees Ctherine McLughlin nd Adm Swinurn, June 2014 Employer-sponsored helth insurnce (ESI) is the dominnt source of coverge for nonelderly dults

More information

Treating Prostate Cancer

Treating Prostate Cancer CHAPTER 4 Treting Prostte Cncer here is controversy bout the optiml tretment for cliniclly loclized prostte cncer (i.e., cncer tht ppers not to hve spred beyond the prostte bsed on informtion vilble without

More information

Lump-Sum Distributions at Job Change, p. 2

Lump-Sum Distributions at Job Change, p. 2 Jnury 2009 Vol. 30, No. 1 Lump-Sum Distributions t Job Chnge, p. 2 E X E C U T I V E S U M M A R Y Lump-Sum Distributions t Job Chnge GROWING NUMBER OF WORKERS FACED WITH ASSET DECISIONS AT JOB CHANGE:

More information

Health Information Systems: evaluation and performance of a Help Desk

Health Information Systems: evaluation and performance of a Help Desk 536 Digitl Helthcre Empowering Europens R. Cornet et l. (Eds.) 2015 Europen Federtion for Medicl Informtics (EFMI). This rticle is published online with Open Access by IOS Press nd distributed under the

More information

Unit 29: Inference for Two-Way Tables

Unit 29: Inference for Two-Way Tables Unit 29: Inference for Two-Wy Tbles Prerequisites Unit 13, Two-Wy Tbles is prerequisite for this unit. In ddition, students need some bckground in significnce tests, which ws introduced in Unit 25. Additionl

More information

An Undergraduate Curriculum Evaluation with the Analytic Hierarchy Process

An Undergraduate Curriculum Evaluation with the Analytic Hierarchy Process An Undergrdute Curriculum Evlution with the Anlytic Hierrchy Process Les Frir Jessic O. Mtson Jck E. Mtson Deprtment of Industril Engineering P.O. Box 870288 University of Albm Tuscloos, AL. 35487 Abstrct

More information

MAX. As an increasingly larger share of Medicaid enrollees MEDICAID POLICY BRIEF

MAX. As an increasingly larger share of Medicaid enrollees MEDICAID POLICY BRIEF MAX CENTERS FOR MEDICARE & MEDICAID SERVICES MEDICAID POLICY BRIEF Brief 14 December 2012 The Avilbility nd Usbility of Behviorl Helth Orgniztion Encounter Dt in MAX 2009 Jessic Nysenbum, Ellen Bouchery,

More information

Navy Asbestos Medical Surveillance Program 1990 1999: Demographic Features and Trends in Abnormal Radiographic Findings

Navy Asbestos Medical Surveillance Program 1990 1999: Demographic Features and Trends in Abnormal Radiographic Findings MILITARY MEDICINE, 171, 8:717, 2006 Nvy Asbestos Medicl Surveillnce Progrm 1990 1999: Demogrphic Fetures nd Trends in Abnorml Rdiogrphic Findings Gurntor: Dnielle M. Dell, MPH Contributors: Dnielle M.

More information

Experiment 6: Friction

Experiment 6: Friction Experiment 6: Friction In previous lbs we studied Newton s lws in n idel setting, tht is, one where friction nd ir resistnce were ignored. However, from our everydy experience with motion, we know tht

More information

A COMPARISON OF ALCOHOL SCREENING INSTRUMENTS AMONG UNDER-AGED DRINKERS TREATED IN EMERGENCY DEPARTMENTS

A COMPARISON OF ALCOHOL SCREENING INSTRUMENTS AMONG UNDER-AGED DRINKERS TREATED IN EMERGENCY DEPARTMENTS Alcohol & Alcoholism Vol. 37, No. 5, pp. 444 450, 2002 A COMPARISON OF ALCOHOL SCREENING INSTRUMENTS AMONG UNDER-AGED DRINKERS TREATED IN EMERGENCY DEPARTMENTS THOMAS M. KELLY 1 *, JOHN E. DONOVAN 1, JANET

More information

MEDICAL SURVEILLANCE MONTHLY REPORT

MEDICAL SURVEILLANCE MONTHLY REPORT AUGUST 2015 Volume 22 Number 8 msmr MEDICAL SURVEILLANCE MONTHLY REPORT PAGE 2 PAGE 9 Updte: Routine screening for ntibodies to humn immunodeficiency virus, civilin pplicnts for U.S. militry service nd

More information

Survival of Non-small Cell Lung Cancer Patients with Postoperative Recurrence at Distant Organs

Survival of Non-small Cell Lung Cancer Patients with Postoperative Recurrence at Distant Organs Survivl of Non-smll Cell Cncer Ptients with Postopertive Recurrence t Distnt Orgns Ichiro Yoshino, MD, 1,2 Tomofumi Yohen, MD, 1 Mschik Kitjim, MD, 1 Chie Ushijim, MD, 1 Kenichi Nishiok, MD, 1 Yukito Ichinose,

More information

2015 EDITION. AVMA Report on Veterinary Compensation

2015 EDITION. AVMA Report on Veterinary Compensation 2015 EDITION AVMA Report on Veterinry Compenstion AVMA Report on Veterinry Compenstion 2015 EDITION Copyright 2015 by the All rights reserved. ISBN-13: 978-1-882691-31-9 AVMA Report on Veterinry Compenstion

More information

UNITED STATES DEPARTMENT OF AGRICULTURE Washington, D.C. 20250. ACTION BY: All Divisions and Offices. FGIS Directive 2510.

UNITED STATES DEPARTMENT OF AGRICULTURE Washington, D.C. 20250. ACTION BY: All Divisions and Offices. FGIS Directive 2510. UNITED STATES DEPARTMENT OF AGRICULTURE Wshington, D.C. 20250 ACTION BY: All Divisions nd Offices FGIS Directive 2510.1 12-11-73 FEDERAL TORT CLAIMS I PURPOSE This Instruction: A Sets forth the bsic provisions

More information

persons withdrawing from addiction is given by summarizing over individuals with different ages and numbers of years of addiction remaining:

persons withdrawing from addiction is given by summarizing over individuals with different ages and numbers of years of addiction remaining: COST- BENEFIT ANALYSIS OF NARCOTIC ADDICTION TREATMENT PROGRAMS with Specil Reference to Age Irving Leveson,l New York City Plnning Commission Introduction Efforts to del with consequences of poverty,

More information

FDIC Study of Bank Overdraft Programs

FDIC Study of Bank Overdraft Programs FDIC Study of Bnk Overdrft Progrms Federl Deposit Insurnce Corportion November 2008 Executive Summry In 2006, the Federl Deposit Insurnce Corportion (FDIC) initited two-prt study to gther empiricl dt on

More information

Defining treatment-resistant depression: A comprehensive review of the literature

Defining treatment-resistant depression: A comprehensive review of the literature ANNALS OF CLINICAL PSYCHIATRY 2014;26(3):222-232 REVIEW ARTICLE Defining tretment-resistnt depression: A comprehensive review of the literture Kenneth Trevino, PhD Shwn M. McClintock, PhD, MSCS Noelle

More information

Family Practice Advance Access published March 17, 2015

Family Practice Advance Access published March 17, 2015 Fmily Prctice Advnce Access published Mrch 17, 2015 Fmily Prctice, 2015, 1 5 doi:10.1093/fmpr/cmv010 Thyroid function testing in primry cre: overused nd under-evidenced? A study exmining which clinicl

More information

Mental Health Issue MEDICAL SURVEILLANCE MONTHLY REPORT JULY 2013. Editorial: the mental health of our deploying generation

Mental Health Issue MEDICAL SURVEILLANCE MONTHLY REPORT JULY 2013. Editorial: the mental health of our deploying generation JULY 2013 Volume 20 Number 7 msmr MEDICAL SURVEILLANCE MONTHLY REPORT Mentl Helth Issue PAGE 2 Editoril: the mentl helth of our deploying genertion Richrd F. Stoltz, PhD PAGE 4 Summry of mentl disorder

More information

Vendor Rating for Service Desk Selection

Vendor Rating for Service Desk Selection Vendor Presented By DATE Using the scores of 0, 1, 2, or 3, plese rte the vendor's presenttion on how well they demonstrted the functionl requirements in the res below. Also consider how efficient nd functionl

More information

Small Business Networking

Small Business Networking Why Network is n Essentil Productivity Tool for Any Smll Business TechAdvisory.org SME Reports sponsored by Effective technology is essentil for smll businesses looking to increse their productivity. Computer

More information

Health insurance exchanges What to expect in 2014

Health insurance exchanges What to expect in 2014 Helth insurnce exchnges Wht to expect in 2014 33096CAEENABC 11/12 The bsics of exchnges As prt of the Affordble Cre Act (ACA or helth cre reform lw), strting in 2014 ALL Americns must hve minimum mount

More information

The LENA TM Language Environment Analysis System:

The LENA TM Language Environment Analysis System: FOUNDATION The LENA TM Lnguge Environment Anlysis System: Audio Specifictions of the DLP-0121 Michel Ford, Chrles T. Ber, Dongxin Xu, Umit Ypnel, Shrmi Gry LENA Foundtion, Boulder, CO LTR-03-2 September

More information

2. Transaction Cost Economics

2. Transaction Cost Economics 3 2. Trnsction Cost Economics Trnsctions Trnsctions Cn Cn Be Be Internl Internl or or Externl Externl n n Orgniztion Orgniztion Trnsctions Trnsctions occur occur whenever whenever good good or or service

More information

Subjective health complaints and psychosocial work environment among university personnel

Subjective health complaints and psychosocial work environment among university personnel Occuptionl Medicine Advnce Access published November 8, 2012 Occuptionl Medicine doi:10.1093/occmed/kqs188 Subjective helth complints nd psychosocil work environment mong university personnel Bente E.

More information

Hematopoietic stem cell transplantation

Hematopoietic stem cell transplantation Online Clinicl Investigtions Improved outcomes for stem cell trnsplnt recipients requiring peditric intensive cre Rnjit S. Chim, MD; Rodney C. Dniels, MD; Mi-Ok Kim, PhD; Dndn Li, MS; Derek S. Wheeler,

More information

Small Business Networking

Small Business Networking Why network is n essentil productivity tool for ny smll business Effective technology is essentil for smll businesses looking to increse the productivity of their people nd processes. Introducing technology

More information

Chapter 8 - Practice Problems 1

Chapter 8 - Practice Problems 1 Chpter 8 - Prctice Problems 1 MULTIPLE CHOICE. Choose the one lterntive tht best completes the sttement or nswers the question. A hypothesis test is to be performed. Determine the null nd lterntive hypotheses.

More information

Small Business Networking

Small Business Networking Why network is n essentil productivity tool for ny smll business Effective technology is essentil for smll businesses looking to increse the productivity of their people nd processes. Introducing technology

More information

98 L.L. Judd et al. / Journal of Affective Disorders 50 (1998) 97 108

98 L.L. Judd et al. / Journal of Affective Disorders 50 (1998) 97 108 Journl of Affective Disorders 50 (1998) 97 108 Reserch report Mjor depressive disorder: A prospective study of residul subthreshold depressive symptoms s predictor of rpid relpse,b, b,c b Lewis L. Judd

More information

9 CONTINUOUS DISTRIBUTIONS

9 CONTINUOUS DISTRIBUTIONS 9 CONTINUOUS DISTIBUTIONS A rndom vrible whose vlue my fll nywhere in rnge of vlues is continuous rndom vrible nd will be ssocited with some continuous distribution. Continuous distributions re to discrete

More information

Copyright@United Nations, 2015. All rights reserved ANNEXES

Copyright@United Nations, 2015. All rights reserved ANNEXES ANNEXES ANNEX CLASSIFICATION AND LABELLING SUMMARY TABLES Annex CLASSIFICATION AND LABELLING SUMMARY TABLES NOTE: The codifiction of hzrd s is further explined in Annex 3 (Section ). The hzrd re intended

More information

Small Business Networking

Small Business Networking Why network is n essentil productivity tool for ny smll business Effective technology is essentil for smll businesses looking to increse the productivity of their people nd processes. Introducing technology

More information

Why is the NSW prison population falling?

Why is the NSW prison population falling? NSW Bureu of Crime Sttistics nd Reserch Bureu Brief Issue pper no. 80 September 2012 Why is the NSW prison popultion flling? Jcqueline Fitzgerld & Simon Corben 1 Aim: After stedily incresing for more thn

More information

INJURY MANAGEMENT & REHABILITATION

INJURY MANAGEMENT & REHABILITATION OBJECTIVES To estblish systemtic pproch to injury mngement nd rehbilittion throughout the City immeditely following work relted illness, injury nd disbility. To estblish tht it is the responsibility of

More information

Predictive factors of abstinence in patients undergoing liver transplantation for alcoholic liver disease

Predictive factors of abstinence in patients undergoing liver transplantation for alcoholic liver disease ORIGINAL ARTICLE Abstinence in ptients undergoing liver trnsplnttion., 2012; 11 (2): 213-221 Mrch-April, Vol. 11 No.2, 2012: 213-221 213 Predictive fctors of bstinence in ptients undergoing liver trnsplnttion

More information

Long-Term Prognosis for Clinical West Nile Virus Infection. 1 Current affiliation: U.S. Department of Veteran Affairs, West

Long-Term Prognosis for Clinical West Nile Virus Infection. 1 Current affiliation: U.S. Department of Veteran Affairs, West Long-Term Prognosis for Clinicl West Nile Virus Infection Anne Lbowitz Klee,* 1 Beth Mldin,* Brbr Edwin,* Iqbl Poshni,* Frzd Mostshri,* Annie Fine,* Mrcelle Lyton,* nd Denis Nsh* 2 Reltively little is

More information

Small Business Networking

Small Business Networking Why network is n essentil productivity tool for ny smll business Effective technology is essentil for smll businesses looking to increse the productivity of their people nd business. Introducing technology

More information

Fatal Crashes from Drivers Testing Positive for Drugs in the U.S., 1993 2010

Fatal Crashes from Drivers Testing Positive for Drugs in the U.S., 1993 2010 Reserch Articles Ftl Crshes from Drivers Testing Positive for Drugs in the U.S., 1993 2010 Fernndo A. Wilson, PhD Jim P. Stimpson, PhD José A. Pgán, PhD b ABSTRACT Objective. Illegl drug use is persistent

More information

274 Chapter 13. Chapter 13

274 Chapter 13. Chapter 13 74 hpter 3 hpter 3 3. () ounts will be obtined from the smples so th problem bout compring proportions. (b) h n observtionl study compring rndom smples selected from two independent popultions. 3. () cores

More information

July 22, 2009. The Honorable Henry A. Waxman Chairman Committee on Energy and Commerce House of Representatives

July 22, 2009. The Honorable Henry A. Waxman Chairman Committee on Energy and Commerce House of Representatives United Sttes Government Accountbility Office Wshington, DC 20548 July 22, 2009 The Honorble Henry A. Wxmn Chirmn Committee on Energy nd Commerce House of Representtives The Honorble John D. Dingell Chirmn

More information

Management and treatment goals in Polish patients with type 2 diabetes of more than ten years duration results of ARETAEUS2-Grupa Study

Management and treatment goals in Polish patients with type 2 diabetes of more than ten years duration results of ARETAEUS2-Grupa Study Prce oryginlne/originl ppers Endokrynologi Polsk DOI: 10.5603/EP.2014.0022 Tom/Volume 65; Numer/Number 3/2014 ISSN 0423 104X Mngement nd tretment gols in Polish ptients with type 2 dibetes of more thn

More information

Helicopter Theme and Variations

Helicopter Theme and Variations Helicopter Theme nd Vritions Or, Some Experimentl Designs Employing Pper Helicopters Some possible explntory vribles re: Who drops the helicopter The length of the rotor bldes The height from which the

More information

Quality and Cost Evaluation of a Medical Financial Assistance Program

Quality and Cost Evaluation of a Medical Financial Assistance Program Qulity nd Cost Evlution of Medicl Finncil Assistnce Progrm Dougls A Conner, PhD; Arne Beck, PhD; Christin Clrke; Leslie Wright, MA; Koml Nrwney, MD, PhD; Neys W Berminghm Perm J 2013 Winter;17(1):31-37

More information

Enterprise Risk Management Software Buyer s Guide

Enterprise Risk Management Software Buyer s Guide Enterprise Risk Mngement Softwre Buyer s Guide 1. Wht is Enterprise Risk Mngement? 2. Gols of n ERM Progrm 3. Why Implement ERM 4. Steps to Implementing Successful ERM Progrm 5. Key Performnce Indictors

More information

Walnut Consumption Increases Satiation but Has No Effect on Insulin Resistance or the Metabolic Profile Over a 4-day Period

Walnut Consumption Increases Satiation but Has No Effect on Insulin Resistance or the Metabolic Profile Over a 4-day Period nture publishing group Wlnut Consumption Increses Stition but Hs No Effect on Insulin Resistnce or the Metbolic Profile Over 4-dy Period Aoife M. Brennn 1, Lur L. Sweeney 1, Xiowen Liu 1 nd Christos S.

More information

Understanding Life Cycle Costs How a Northern Pump Saves You Money

Understanding Life Cycle Costs How a Northern Pump Saves You Money Understnding Life Cycle Costs How Nrn Pump Sves You Money Reference: Hydrulic Institute (www.s.g) Introduction Wht Life Cycle Cost (LCC) Clculting Totl LCC LCC Components Wht Life Cycle Cost Life Cycle

More information

Pressure Ulcers ecourse: Module 2 Quiz I

Pressure Ulcers ecourse: Module 2 Quiz I Pressure Ulcers ecourse: Module 2 Quiz I 1. Blck, brown or tn tissue tht dheres firmly to the wound bed or ulcer edges nd my be either firmer or softer thn surrounding tissue is:. Eschr b. Slough c. Grnultion

More information

Small Business Networking

Small Business Networking Why network is n essentil productivity tool for ny smll business Effective technology is essentil for smll businesses looking to increse the productivity of their people nd business. Introducing technology

More information

Unit 10 Identification of Unexpected Alloantibodies

Unit 10 Identification of Unexpected Alloantibodies Unit 10 Identifiction of Unexpected Allontibodies A. Introduction 1. Unexpected llontibodies re ntibodies other thn nturlly occurring nti-a or -B. 2. Such ntibodies re found in some 0.3-2% of the popultion,

More information

Below, this letter outlines [patient name] s medical history, prognosis, and treatment rationale.

Below, this letter outlines [patient name] s medical history, prognosis, and treatment rationale. [Date] [Name of Contact] [Title] [Name of Health Insurance Company] [Address] [City, State, Zip Code] Insured: [Patient Name] Policy Number: [Number] Group Number: [Number] Diagnosis: [Diagnosis and ICD-9-CM

More information

Polynomial Functions. Polynomial functions in one variable can be written in expanded form as ( )

Polynomial Functions. Polynomial functions in one variable can be written in expanded form as ( ) Polynomil Functions Polynomil functions in one vrible cn be written in expnded form s n n 1 n 2 2 f x = x + x + x + + x + x+ n n 1 n 2 2 1 0 Exmples of polynomils in expnded form re nd 3 8 7 4 = 5 4 +

More information

Economics Letters 65 (1999) 9 15. macroeconomists. a b, Ruth A. Judson, Ann L. Owen. Received 11 December 1998; accepted 12 May 1999

Economics Letters 65 (1999) 9 15. macroeconomists. a b, Ruth A. Judson, Ann L. Owen. Received 11 December 1998; accepted 12 May 1999 Economics Letters 65 (1999) 9 15 Estimting dynmic pnel dt models: guide for q mcroeconomists b, * Ruth A. Judson, Ann L. Owen Federl Reserve Bord of Governors, 0th & C Sts., N.W. Wshington, D.C. 0551,

More information

Chromebook Parent/Student Information

Chromebook Parent/Student Information Chromebook Prent/Student Informtion 1 Receiving Your Chromebook Student Distribution Students will receive their Chromebooks nd cses during school. Students nd prents must sign the School City of Hmmond

More information

Antibody Screening. Antibody Screening in Pre-transfusion Testing and Antenatal Screening

Antibody Screening. Antibody Screening in Pre-transfusion Testing and Antenatal Screening Antiody Screening in Pre-trnsfusion Testing nd Antentl Screening Antiody Screening in Pre-trnsfusion Testing nd Antentl Screening Q. Wht re nturlly occurring or expected ntiodies? Q. Wht re typicl or unexpected

More information

Test Management using Telelogic DOORS. Francisco López Telelogic DOORS Specialist

Test Management using Telelogic DOORS. Francisco López Telelogic DOORS Specialist Test Mngement using Telelogic DOORS Frncisco López Telelogic DOORS Specilist Introduction Telelogic solution for Requirements Mngement DOORS Requirements mngement nd trcebility pltform for complex systems

More information

JaERM Software-as-a-Solution Package

JaERM Software-as-a-Solution Package JERM Softwre-s--Solution Pckge Enterprise Risk Mngement ( ERM ) Public listed compnies nd orgnistions providing finncil services re required by Monetry Authority of Singpore ( MAS ) nd/or Singpore Stock

More information

Prevalence of Skin Disease among Nursing Home Staff in Southern Taiwan

Prevalence of Skin Disease among Nursing Home Staff in Southern Taiwan Industril Helth 2002, 40, 54 58 Short Communiction Prevlence of Skin Disese mong Nursing Home Stff in Southern Tiwn Derek Richrd SMITH 1, 2, Yue-Ling Leon GUO 2, 3, Yung-Ling LEE 2, 3, Fu-Sen HSIEH 4,

More information

An elevated basal FSH re ects a quantitative rather than qualitative decline of the ovarian reserve

An elevated basal FSH re ects a quantitative rather than qualitative decline of the ovarian reserve Humn Reproduction Vol.19, No.4 pp. 893±898, 2004 Advnce Access publiction Mrch 11, 2004 DOI: 10.1093/humrep/deh141 An elevted bsl FSH re ects quntittive rther thn qulittive decline of the ovrin reserve

More information

Copyright@United Nations 2013. All rights reserved ANNEXES

Copyright@United Nations 2013. All rights reserved ANNEXES ANNEXES ANNEX 1 CLASSIFICATION AND LABELLING SUMMARY TABLES Annex 1 CLASSIFICATION AND LABELLING SUMMARY TABLES NOTE: The codifiction of hzrd s is further explined in Annex 3 (Section 1). The hzrd re

More information

July 2005, NCJ 209588 Substance Dependence, Abuse, and Treatment of Jail Inmates, 2002. Highlights. No dependence or abuse 53 47 32.

July 2005, NCJ 209588 Substance Dependence, Abuse, and Treatment of Jail Inmates, 2002. Highlights. No dependence or abuse 53 47 32. U.S. Deprtment of Justice Office of Justice Progrms Bureu of Justice Sttistics Specil Report By Jennifer C. Krerg nd Doris J. Jmes BJS Sttisticins In 2002 more thn two-thirds of jil inmtes were found to

More information

Combined Liability Insurance. Information and Communication Technology Proposal form

Combined Liability Insurance. Information and Communication Technology Proposal form Comined Liility Insurnce Informtion nd Communiction Technology Proposl form Comined Liility Insurnce Informtion nd Communiction Technology - Proposl form This proposl form must e completed nd signed y

More information

Multiple Sclerosis at AAN 2010: Safety, Switching, and Emerging Therapies

Multiple Sclerosis at AAN 2010: Safety, Switching, and Emerging Therapies Multiple Sclerosis t AAN 2010: Sfety, Switching, nd Emerging Therpies Mrk S. Freedmn, MSc, MD Professor of Neurology, University of Ottw, Ottw, Ontrio, Cnd; Director, Multiple Sclerosis Reserch Unit, The

More information

National Diabetes Audit. Report 1: Care Processes and Treatment Targets

National Diabetes Audit. Report 1: Care Processes and Treatment Targets Ntionl Dietes Audit 2012 2013 Report 1: Cre Processes nd Tretment Trgets The Ntionl Dietes Audit is commissioned y The Helthcre Qulity Improvement Prtnership (HQIP) The Ntionl Dietes Audit is commissioned

More information

Immunoglobulins in Umbilical Cord Plasma

Immunoglobulins in Umbilical Cord Plasma Arch. Dis. Childh., 1968, 43, 161. Immunoglobulins in Umbilicl Cord Plsm III: Hemolytic Disese of Newborn nd Respirtory Distress Syndrome RIC McKAY, HAZL THOM, nd DRK GRAY From the Deprtment of Child Helth,

More information

ARTICLE. Introduction

ARTICLE. Introduction Plsm Cell Disorders ARTICLE Cytogenetics nd long-term survivl of ptients with refrctory or relpsed nd refrctory multiple myelom treted with pomlidomide nd low-dose dexmethsone Meletios A. Dimopoulos, 1

More information

The Evolution in Diagnosis and Treatment of Multiple Sclerosis

The Evolution in Diagnosis and Treatment of Multiple Sclerosis The Evolution in Dignosis nd Tretment of Multiple Sclerosis Tiffni Stroup, DO University of Chicgo Medicine, Chicgo, Illinois Abstrct Mngement of multiple sclerosis (MS) hs evolved significntly since the

More information